# 114å¹´ç¬¬äºŒæ¬¡å°ˆé–€è·æ¥­åŠæŠ€è¡“äººå“¡é«˜ç­‰è€ƒè©¦é†«å¸«ä¸­é†«å¸«è€ƒè©¦åˆ†éšæ®µè€ƒè©¦(ç¬¬äºŒéšæ®µè€ƒè©¦) è€ƒå‰çŒœé¡Œ
**æŒ‰ç…§çœŸå¯¦è€ƒè©¦é¡Œæ•¸åˆ†é…ï¼é¡Œè™Ÿèˆ‡è€ƒå¤é¡Œç›¸åŒï¼**<br>
**1å°æ™‚åŠ å¼·å¼±ç§‘è€ƒè©¦é‡é»ï¼**

ã€ŒçŒœé¡Œä¾†æº: è‡¨åºŠã€æ„æŒ‡ä»¥å¯¦ç¿’ç¶“é©—(å«é–€è¨ºåŠä½é™¢)åŠä¸Šèª²å…§å®¹ç‚ºä¸»ä»¥è€ƒå¤é¡ŒåŠ114-2æ–°è€ƒç¶±ç‚ºè¼”ä¹‹çŒœé¡Œ<br>
ã€ŒçŒœé¡Œä¾†æº: è€ƒå¤é¡Œã€æ„æŒ‡ä»¥è€ƒå¤é¡ŒåŠ114-2æ–°è€ƒç¶±ç‚ºä¸»ä»¥å¯¦ç¿’ç¶“é©—(å«é–€è¨ºåŠä½é™¢)åŠä¸Šèª²å…§å®¹ç‚ºè¼”ä¹‹çŒœé¡Œ<br>
é™½æ˜é†«å­¸ç³»å…±ç­†å»ºè­°è®€ã€Œé‡é»æ•´ç†ã€<br>
UpToDateå»ºè­°è®€ã€ŒSUMMARY AND RECOMMENDATIONSã€
## é†«å­¸(ä¸‰)
### ã€€ å…§ç§‘
#### ã€€ã€€ä¸€èˆ¬å…§ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
1. Stress ulcers in the intensive care unit: Diagnosis, management, and prevention ([UpToDate](https://www.uptodate.com/contents/stress-ulcers-in-the-intensive-care-unit-diagnosis-management-and-prevention))
2. Pulmonary artery catheterization: Indications, contraindications, and complications in adults ([UpToDate](https://www.uptodate.com/contents/pulmonary-artery-catheterization-indications-contraindications-and-complications-in-adults))
3. Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis ([UpToDate](https://www.uptodate.com/contents/sepsis-syndromes-in-adults-epidemiology-definitions-clinical-presentation-diagnosis-and-prognosis))
4. Maintenance and replacement fluid therapy in adults ([UpToDate](https://www.uptodate.com/contents/maintenance-and-replacement-fluid-therapy-in-adults))
5. Use of vasopressors and inotropes ([UpToDate](https://www.uptodate.com/contents/use-of-vasopressors-and-inotropes))
#### å¿ƒè‡Ÿå…§ç§‘ (çŒœé¡Œä¾†æº: è€ƒå¤é¡Œ)
##### ç¼ºè¡€æ€§å¿ƒè‡Ÿç—…
6. Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults ([UpToDate](https://www.uptodate.com/contents/atherosclerotic-cardiovascular-disease-risk-assessment-for-primary-prevention-in-adults))
7. Overview of the acute management of non-ST-elevation acute coronary syndromes ([UpToDate](https://www.uptodate.com/contents/overview-of-the-acute-management-of-non-st-elevation-acute-coronary-syndromes))
##### å¿ƒè‚Œç—‡
8. Major causes of dilated cardiomyopathy ([UpToDate](https://www.uptodate.com/contents/image?imageKey=CARD/60494&topicKey=CARD%2F3516&search=dilated+cardiomyopathy&source=outline_link&selectedTitle=1%7E150))
##### å¿ƒé›»åœ–
9. Overview of cardiac arrhythmias ([Amboss](https://next.amboss.com/us/article/7S04af))
##### é«˜è¡€å£“
10. Overview of hypertension in adults ([UpToDate](https://www.uptodate.com/contents/overview-of-hypertension-in-adults))
##### è¡€ç®¡ç—…
11. Aneurysm ([Amboss](https://next.amboss.com/us/article/Wh0P1f))
##### å¿ƒåŒ…ç–¾ç—…
12. Acute pericarditis: Clinical presentation and diagnosis ([UpToDate](https://www.uptodate.com/contents/acute-pericarditis-clinical-presentation-and-diagnosis))
##### å¿ƒè¡°ç«­
13. Clinical manifestations and diagnosis of advanced heart failure ([UpToDate](https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-advanced-heart-failure))
##### å¿ƒå¾‹ä¸æ•´
14. Atrial fibrillation: Overview and management of new-onset atrial fibrillation ([UpToDate](https://www.uptodate.com/contents/atrial-fibrillation-overview-and-management-of-new-onset-atrial-fibrillation))
#### èƒƒè…¸ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
15. Hepatitis B virus: Overview of management ([UpToDate](https://www.uptodate.com/contents/hepatitis-b-virus-overview-of-management))
16. Diagnostic approach to the adult with jaundice or asymptomatic hyperbilirubinemia ([UpToDate](https://www.uptodate.com/contents/diagnostic-approach-to-the-adult-with-jaundice-or-asymptomatic-hyperbilirubinemia))
17. Treatment of irritable bowel syndrome in adults ([UpToDate](https://www.uptodate.com/contents/treatment-of-irritable-bowel-syndrome-in-adults))
18. Spontaneous bacterial peritonitis in adults: Treatment and prophylaxis ([UpToDate](https://www.uptodate.com/contents/spontaneous-bacterial-peritonitis-in-adults-treatment-and-prophylaxis))
19. Clinical manifestations, diagnosis, and staging of esophageal cancer ([UpToDate](https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-staging-of-esophageal-cancer))
20. Overview of the management of patients with variceal bleeding ([UpToDate](https://www.uptodate.com/contents/overview-of-the-management-of-patients-with-variceal-bleeding))
21. Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer ([UpToDate](https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-staging-of-exocrine-pancreatic-cancer))
22. Overview of treatment approaches for hepatocellular carcinoma ([UpToDate](https://www.uptodate.com/contents/overview-of-treatment-approaches-for-hepatocellular-carcinoma))
23. Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis ([UpToDate](https://www.uptodate.com/contents/cirrhosis-in-adults-etiologies-clinical-manifestations-and-diagnosis))
#### è…è‡Ÿç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
24. Overview of the management of acute kidney injury (AKI) in adults ([UpToDate](https://www.uptodate.com/contents/overview-of-the-management-of-acute-kidney-injury-aki-in-adults))
25. Overview of heavy proteinuria and the nephrotic syndrome ([UpToDate](https://www.uptodate.com/contents/overview-of-heavy-proteinuria-and-the-nephrotic-syndrome))
26. Overview of the management of chronic kidney disease in adults ([UpToDate](https://www.uptodate.com/contents/overview-of-the-management-of-chronic-kidney-disease-in-adults))
27. Dialysis modality and patient outcome ([UpToDate](https://www.uptodate.com/contents/dialysis-modality-and-patient-outcome))
28. Approach to the adult with metabolic acidosis ([UpToDate](https://www.uptodate.com/contents/approach-to-the-adult-with-metabolic-acidosis))
29. Diagnostic evaluation of adults with hyponatremia ([UpToDate](https://www.uptodate.com/contents/diagnostic-evaluation-of-adults-with-hyponatremia))
30. Kidney stones in adults: Prevention of recurrent kidney stones ([UpToDate](https://www.uptodate.com/contents/kidney-stones-in-adults-prevention-of-recurrent-kidney-stones))
#### éæ•å…ç–«é¢¨æ¿•ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
##### çµç· çµ„ç¹”ç—…
31. Systemic lupus erythematosus in adults: Clinical manifestations and diagnosis ([UpToDate](https://www.uptodate.com/contents/systemic-lupus-erythematosus-in-adults-clinical-manifestations-and-diagnosis))
32. Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults ([UpToDate](https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-systemic-sclerosis-scleroderma-in-adults))
33. Overview of the management and prognosis of SjÃ¶gren's disease ([UpToDate](https://www.uptodate.com/contents/overview-of-the-management-and-prognosis-of-sjogrens-disease))
##### é—œç¯€ç‚
34. Diagnosis and differential diagnosis of rheumatoid arthritis ([UpToDate](https://www.uptodate.com/contents/diagnosis-and-differential-diagnosis-of-rheumatoid-arthritis))
35. Overview of the clinical manifestations and classification of spondyloarthritis ([UpToDate](https://www.uptodate.com/contents/overview-of-the-clinical-manifestations-and-classification-of-spondyloarthritis))
#### è…«ç˜¤ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
36. Overview of the classification and management of cancers of unknown primary site ([UpToDate](https://www.uptodate.com/contents/overview-of-the-classification-and-management-of-cancers-of-unknown-primary-site))
37. Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer ([UpToDate](https://www.uptodate.com/contents/overview-of-the-treatment-of-newly-diagnosed-invasive-non-metastatic-breast-cancer))
38. Overview of the initial treatment and prognosis of lung cancer ([UpToDate](https://www.uptodate.com/contents/overview-of-the-initial-treatment-and-prognosis-of-lung-cancer))
39. Overview of the management of primary colon cancer ([UpToDate](https://www.uptodate.com/contents/overview-of-the-management-of-primary-colon-cancer))
40. Clinical presentation, diagnosis, and staging of gastric cancer ([UpToDate](https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-staging-of-gastric-cancer))
41. Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer ([UpToDate](https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-staging-of-exocrine-pancreatic-cancer))
#### è¡€æ¶²ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
##### Platelet
42. Hemostasis and bleeding disorders ([Amboss](https://next.amboss.com/us/article/8T0Os2))
##### RBC
43. Microcytosis/Microcytic anemia ([UpToDate](https://www.uptodate.com/contents/microcytosis-microcytic-anemia))
##### WBC
44. Acute leukemia ([Amboss](https://next.amboss.com/us/article/iT0Jq2))
#### èƒ¸è…”å…§ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
45. Overview of community-acquired pneumonia in adults ([UpToDate](https://www.uptodate.com/contents/overview-of-community-acquired-pneumonia-in-adults))
46. The evaluation, diagnosis, and treatment of the adult patient with acute hypercapnic respiratory failure ([UpToDate](https://www.uptodate.com/contents/the-evaluation-diagnosis-and-treatment-of-the-adult-patient-with-acute-hypercapnic-respiratory-failure))
47. Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults ([UpToDate](https://www.uptodate.com/contents/acute-respiratory-distress-syndrome-clinical-features-diagnosis-and-complications-in-adults))
48. Pleural fluid analysis in adults with a pleural effusion ([UpToDate](https://www.uptodate.com/contents/pleural-fluid-analysis-in-adults-with-a-pleural-effusion))
49. Treatment of primary spontaneous pneumothorax in adults ([UpToDate](https://www.uptodate.com/contents/treatment-of-primary-spontaneous-pneumothorax-in-adults))
50. Chronic obstructive pulmonary disease: Diagnosis and staging ([UpToDate](https://www.uptodate.com/contents/chronic-obstructive-pulmonary-disease-diagnosis-and-staging))
51. An overview of asthma management in children and adults ([UpToDate](https://www.uptodate.com/contents/an-overview-of-asthma-management-in-children-and-adults))
#### æ–°é™³ä»£è¬ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
##### Diabetes
52. Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults ([UpToDate](https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-initial-evaluation-of-diabetes-mellitus-in-adults))
53. Metabolic syndrome (insulin resistance syndrome or syndrome X) ([UpToDate](https://www.uptodate.com/contents/metabolic-syndrome-insulin-resistance-syndrome-or-syndrome-x))
54. Obesity in adults: Overview of management ([UpToDate](https://www.uptodate.com/contents/obesity-in-adults-overview-of-management))
##### Dyslipidemia
55. Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease ([UpToDate](https://www.uptodate.com/contents/low-density-lipoprotein-cholesterol-lowering-therapy-in-the-primary-prevention-of-cardiovascular-disease))
##### Endocrine
56. Laboratory assessment of thyroid function ([UpToDate](https://www.uptodate.com/contents/laboratory-assessment-of-thyroid-function?search=thyroid))
57. Treatment of hypocalcemia ([UpToDate](https://www.uptodate.com/contents/treatment-of-hypocalcemia))
58. Causes of primary adrenal insufficiency (Addison disease) ([UpToDate](https://www.uptodate.com/contents/causes-of-primary-adrenal-insufficiency-addison-disease))
#### æ„ŸæŸ“ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
59. Acute and early HIV infection: Clinical manifestations and diagnosis ([UpToDate](https://www.uptodate.com/contents/acute-and-early-hiv-infection-clinical-manifestations-and-diagnosis))
60. Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening) ([UpToDate](https://www.uptodate.com/contents/tuberculosis-infection-latent-tuberculosis-in-adults-approach-to-diagnosis-screening))
61. Infection prevention: Precautions for preventing transmission of infection ([UpToDate](https://www.uptodate.com/contents/infection-prevention-precautions-for-preventing-transmission-of-infection))
62. Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects ([UpToDate](https://www.uptodate.com/contents/beta-lactam-antibiotics-mechanisms-of-action-and-resistance-and-adverse-effects))
63. Overview of community-acquired pneumonia in adults ([UpToDate](https://www.uptodate.com/contents/overview-of-community-acquired-pneumonia-in-adults))
64. Screening for sexually transmitted infections ([UpToDate](https://www.uptodate.com/contents/screening-for-sexually-transmitted-infections))
65. ç—…æ¯’å­¸åœ‹è€ƒç¸½è¤‡ç¿’ ([é™½æ˜é†«å­¸ç³»é»ƒéº—è¯è€å¸«](å…§éƒ¨/é™½æ˜é†«å­¸ç³»112ç´šä¸Šèª²è¬›ç¾©/2019%20ç—…æ¯’å­¸åœ‹è€ƒè¤‡ç¿’çµ¦é†«äºŒ.pdf))
### å®¶åº­é†«å­¸ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
#### å®¶åº­é†«æ¥­
66. å®¶åº­é†«å­¸çš„ç…§é¡§ç‰¹è‰²ï¼š3C2A ([å…§éƒ¨](å…§éƒ¨/3C2A.md))
67. Obesity in adults: Overview of management ([UpToDate](https://www.uptodate.com/contents/obesity-in-adults-overview-of-management))
#### é é˜²é†«å­¸
68. å¬°å¹¼å…’é é˜²æ¥ç¨®æ™‚ç¨‹æµ·å ± ([è¡›ç¦éƒ¨ç–¾ç®¡ç½²](https://www.cdc.gov.tw/File/Get?q=alK1SUhIV6SOP0j4uU3aI7aYD5CNmxXJXAgbcPCy5Mj5d0TnNiVZy5aDEBVIlSO5kZ5pqAGpOQ5FCdQNl36pYTqGkKJSBG2iwtQWOlb2AxTU1U8YzzGWTk5x42GrqevBKYo-tRf_00xVLuwnra5t3g)(ä¸‹è¼‰jpgæª”))
69. A and B Recommendations ([USPSTF](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations) [USPSTF](https://www.uspreventiveservicestaskforce.org/webview))
#### è¡Œç‚ºé†«å­¸
70. Glossary of common biostatistical and epidemiological terms ([UpToDate](https://www.uptodate.com/contents/glossary-of-common-biostatistical-and-epidemiological-terms))
71. Depression in adults: Clinical features and diagnosis ([UpToDate](https://www.uptodate.com/contents/depression-in-adults-clinical-features-and-diagnosis))
#### ç¤¾å€é†«å­¸
72. Metabolic syndrome (insulin resistance syndrome or syndrome X) ([UpToDate](https://www.uptodate.com/contents/metabolic-syndrome-insulin-resistance-syndrome-or-syndrome-x))
#### ç·©å’Œé†«å­¸
73. å®‰å¯§ç·©å’Œé†«ç™‚æ¢ä¾‹ ([å…¨åœ‹æ³•è¦è³‡æ–™åº«](https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0020066))
### æ”¾å°„ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
#### è…¹éƒ¨å½±åƒé†«å­¸
74. Hepatic hemangioma ([Radiopaedia](https://radiopaedia.org/articles/hepatic-haemangioma))
75. Hepatocellular carcinoma ([Radiopaedia](https://radiopaedia.org/articles/hepatocellular-carcinoma))
### æ€¥è¨ºé†«å­¸ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
#### æ€¥è¨ºå…§ç§‘
76. Adult Cardiac Arrest Algorithm ([AHA](https://cpr.heart.org/-/media/CPR-Images/CPR-Guidelines-Images/Part-3-Adult-Basic-and-Advanced-Life-Support/AlgorithmACLS_CA_200731.jpg)(jpgæª”))
77. Adult Bradycardia Algorithm ([AHA](https://cpr.heart.org/-/media/CPR-Images/CPR-Guidelines-Images/Part-3-Adult-Basic-and-Advanced-Life-Support/Adult_Bradycardia_Algorithm.jpg)(jpgæª”))
78. Acute Coronary Syndrome Algorithm ([å¤–éƒ¨](https://acls-algorithms.com/wp-content/uploads/2022/06/Website-ACS-Algorithm-Diagram.pdf)(pdfæª”))
### é†«å­¸å€«ç†
79. a
80. 



## é†«å­¸(å››)
### ã€€ å°å…’ç§‘
1. a
2. a
3. a
4. a
5. a
6. a
7. a
8. a
9. a
10. a
11. a
12. a
13. a
14. a
15. a
16. a
17. a
18. a
19. a
20. a
21. a
22. a
23. a
24. a
25. a
26. a
27. a
28. a
29. a
30. a
31. a
32. a
33. a
### çš®è†šç§‘ (çŒœé¡Œä¾†æº: è€ƒå¤é¡Œ)
#### æ¿•ç–¹åŠçš®è†šç‚
34. New-onset urticaria (hives) ([UpToDate](https://www.uptodate.com/contents/new-onset-urticaria-hives))
35. Drug hypersensitivity: Classification and clinical features ([UpToDate](https://www.uptodate.com/contents/drug-hypersensitivity-classification-and-clinical-features))
#### æ„ŸæŸ“
##### ç—…æ¯’æ„ŸæŸ“
36. Infectious rashes in childhood ([Amboss](https://next.amboss.com/us/article/QH0uJh))
37. Epidemiology, clinical manifestations, and diagnosis of mpox (formerly monkeypox) ([UpToDate](https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-mpox-formerly-monkeypox))
#### è…«ç˜¤
38. Overview of benign lesions of the skin ([UpToDate](https://www.uptodate.com/contents/overview-of-benign-lesions-of-the-skin))
#### è‡ªé«”å…ç–«ç–¾ç—…
39. Psoriasis: Epidemiology, clinical manifestations, and diagnosis ([UpToDate](https://www.uptodate.com/contents/psoriasis-epidemiology-clinical-manifestations-and-diagnosis))
40. Cutaneous dermatomyositis in adults: Overview and initial management ([UpToDate](https://www.uptodate.com/contents/cutaneous-dermatomyositis-in-adults-overview-and-initial-management))
41. Systemic lupus erythematosus in adults: Clinical manifestations and diagnosis ([UpToDate](https://www.uptodate.com/contents/systemic-lupus-erythematosus-in-adults-clinical-manifestations-and-diagnosis))
#### è‰²ç´ ç–¾ç—…
42. Acquired melanocytic nevi (moles) ([UpToDate](https://www.uptodate.com/contents/acquired-melanocytic-nevi-moles))
#### è§’åŒ–ç•°å¸¸
43. Ichthyosis vulgaris ([UpToDate](https://www.uptodate.com/contents/ichthyosis-vulgaris))
### ç¥ç¶“å…§ç§‘
#### è…¦è¡€ç®¡ç§‘
44. a
45. a
46. a
#### ç™²ç™‡ç§‘
47. a
48. a
49. a
#### ä¸€èˆ¬ç¥ç¶“ç§‘
50. a
51. a
52. a
#### å‘¨é‚Šç¥ç¶“ç§‘
53. a
54. a
55. a
#### ç¥ç¶“å…ç–«ç§‘
56. a
57. a
58. a
### ç²¾ç¥ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
#### Psychotic disorders
59. Psychosis in adults: Epidemiology, clinical manifestations, and diagnostic evaluation ([UpToDate](https://www.uptodate.com/contents/psychosis-in-adults-epidemiology-clinical-manifestations-and-diagnostic-evaluation))
60. Schizophrenia in adults: Clinical features, assessment, and diagnosis ([UpToDate](https://www.uptodate.com/contents/schizophrenia-in-adults-clinical-features-assessment-and-diagnosis))
61. Schizophrenia in adults: Epidemiology and pathogenesis ([UpToDate](https://www.uptodate.com/contents/schizophrenia-in-adults-epidemiology-and-pathogenesis))
#### Neurotic disorders
62. Approach to the adult patient with suspected depression ([UpToDate](https://www.uptodate.com/contents/approach-to-the-adult-patient-with-suspected-depression))
63. Bipolar major depression in adults: Choosing treatment ([UpToDate](https://www.uptodate.com/contents/bipolar-major-depression-in-adults-choosing-treatment))
64. Anxiety disorders in children and adolescents: Assessment and diagnosis ([UpToDate](https://www.uptodate.com/contents/anxiety-disorders-in-children-and-adolescents-assessment-and-diagnosis))
65. Somatic symptom disorder: Assessment and diagnosis ([UpToDate](https://www.uptodate.com/contents/somatic-symptom-disorder-assessment-and-diagnosis))
#### Organic and drug-related disorders
66. Psychiatric drug poisoning ([Amboss](https://next.amboss.com/us/article/qF0CQ3))
67. Substance use disorders: Clinical assessment ([UpToDate](https://www.uptodate.com/contents/substance-use-disorders-clinical-assessment))
68. Ethanol intoxication in adults ([UpToDate](https://www.uptodate.com/contents/ethanol-intoxication-in-adults))
69. COMMON ABUSED SUBSTANCES ([Kaplan](å…§éƒ¨/Kaplan/Kaplan%20USMLE-1%20(2013)%20-%20Behavioral%20Science%20(1).pdf))
70. Evaluation of cognitive impairment and dementia ([UpToDate](https://www.uptodate.com/contents/evaluation-of-cognitive-impairment-and-dementia))
#### å…’é’
71. Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis ([UpToDate](https://www.uptodate.com/contents/attention-deficit-hyperactivity-disorder-in-children-and-adolescents-overview-of-treatment-and-prognosis))
72. Autism spectrum disorder in children and adolescents: Overview of management and prognosis ([UpToDate](https://www.uptodate.com/contents/autism-spectrum-disorder-in-children-and-adolescents-overview-of-management-and-prognosis))
#### å…¶ä»–
73. Suicidal ideation and behavior in adults ([UpToDate](https://www.uptodate.com/contents/suicidal-ideation-and-behavior-in-adults))
### æ”¾å°„ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
#### ç¥ç¶“æ”¾å°„ç§‘
74. Intracranial hemorrhage ([Radiopaedia](https://radiopaedia.org/articles/intracranial-haemorrhage))
75. Extradural hematoma vs subdural hematoma ([Radiopaedia](https://radiopaedia.org/articles/extradural-haematoma-vs-subdural-haematoma))
### æ€¥è¨ºé†«å­¸ç§‘ (çŒœé¡Œä¾†æº: è€ƒå¤é¡Œ)
#### ç²¾ç¥ç§‘æ€¥è¨º
76. Management of neuropsychiatric symptoms of dementia ([UpToDate](https://www.uptodate.com/contents/management-of-neuropsychiatric-symptoms-of-dementia))
77. Panic disorder in adults: Treatment overview ([UpToDate](https://www.uptodate.com/contents/panic-disorder-in-adults-treatment-overview))
#### ç¥ç¶“ç§‘æ€¥è¨º
78. Initial assessment and management of acute stroke ([UpToDate](https://www.uptodate.com/contents/initial-assessment-and-management-of-acute-stroke))
### é†«å­¸å€«ç†
79. a
80. 



## é†«å­¸(äº”)
### ã€€ å¤–ç§‘
#### ã€€ã€€å¤–ç§‘æ¦‚è«–
1. a
2. a
3. a
4. a
5. a
6. a
7. a
#### ç¥ç¶“å¤–ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
##### ç¥ç¶“è…«ç˜¤
###### Intra-axial
8. Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors ([UpToDate](https://www.uptodate.com/contents/classification-and-pathologic-diagnosis-of-gliomas-glioneuronal-tumors-and-neuronal-tumors))
##### è…¦è¡€ç®¡ç—…è®Š
9. Vascular malformations of the central nervous system ([UpToDate](https://www.uptodate.com/contents/vascular-malformations-of-the-central-nervous-system))
10. Carotid-cavernous fistulas ([UpToDate](https://www.uptodate.com/contents/carotid-cavernous-fistulas))
##### è„Šæ¤é€€åŒ–ç–¾ç—…/è„Šé«“æå‚·
11. Degenerative disc disease ([Amboss](https://next.amboss.com/us/article/ji0_rf))
12. Spondylolysis and spondylolisthesis in child and adolescent athletes: Management ([UpToDate](https://www.uptodate.com/contents/spondylolysis-and-spondylolisthesis-in-child-and-adolescent-athletes-management))
##### é ­éƒ¨å¤–å‚·
13. Management of acute moderate and severe traumatic brain injury ([UpToDate](https://www.uptodate.com/contents/management-of-acute-moderate-and-severe-traumatic-brain-injury))
#### é‡å»ºæ•´å½¢å¤–ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
14. Wound healing ([Amboss](https://next.amboss.com/us/article/Kh0UUf))
15. Skin autografting ([UpToDate](https://www.uptodate.com/contents/skin-autografting))
16. Overview of flaps for soft tissue reconstruction ([UpToDate](https://www.uptodate.com/contents/overview-of-flaps-for-soft-tissue-reconstruction))
17. Skin biopsy techniques ([UpToDate](https://www.uptodate.com/contents/skin-biopsy-techniques))
18. Clinical staging and general management of pressure-induced skin and soft tissue injury ([UpToDate](https://www.uptodate.com/contents/clinical-staging-and-general-management-of-pressure-induced-skin-and-soft-tissue-injury))
19. Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis ([UpToDate](https://www.uptodate.com/contents/basal-cell-carcinoma-epidemiology-pathogenesis-clinical-features-and-diagnosis))
#### å¿ƒè‡Ÿè¡€ç®¡å¤–ç§‘ (çŒœé¡Œä¾†æº: è€ƒå¤é¡Œ)
20. Aortic dissection ([Amboss](https://next.amboss.com/us/article/M50Mkg))
21. Endovascular repair of abdominal aortic aneurysm ([UpToDate](https://www.uptodate.com/contents/endovascular-repair-of-abdominal-aortic-aneurysm))
22. Acute limb ischemia ([Amboss](https://next.amboss.com/us/article/1h021f))
23. Management of atrial septal defects in adults ([UpToDate](https://www.uptodate.com/contents/management-of-atrial-septal-defects-in-adults))
24. Choice of prosthetic heart valve for surgical aortic or mitral valve replacement ([UpToDate](https://www.uptodate.com/contents/choice-of-prosthetic-heart-valve-for-surgical-aortic-or-mitral-valve-replacement))
#### èƒ¸è…”å¤–ç§‘ (çŒœé¡Œä¾†æº: è€ƒå¤é¡Œ)
25. Esophageal diverticula ([Amboss](https://next.amboss.com/us/article/Eg08C2))
26. Lung cancer ([Amboss](https://next.amboss.com/us/article/nh07ef))
27. Lung abcess ([Amboss](https://next.amboss.com/us/article/mI0VWh))
28. Pleural effusion ([Amboss](https://next.amboss.com/us/article/F50gNg))
29. Initial evaluation and management of blunt thoracic trauma in adults ([UpToDate](https://www.uptodate.com/contents/initial-evaluation-and-management-of-blunt-thoracic-trauma-in-adults))
#### ä¸€èˆ¬å¤–ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
##### æ¶ˆåŒ–å™¨å¤–ç§‘
###### èƒƒ
30. Gastric cancer ([Amboss](https://next.amboss.com/us/article/-g0DB2))
31. Gastrointestinal stromal tumor ([Amboss](https://next.amboss.com/us/article/iv0J-3))
###### å°è…¸
32. Epidemiology and clinical features of small bowel neoplasms ([UpToDate](https://www.uptodate.com/contents/epidemiology-and-clinical-features-of-small-bowel-neoplasms))
###### èƒ°
33. Pancreatic cancer ([Amboss](https://next.amboss.com/us/article/3S0Sz2))
34. Chronic pancreatitis ([Amboss](https://next.amboss.com/us/article/hS0cz2))
###### è‚
35. Pyogenic liver abscess ([Amboss](https://next.amboss.com/us/article/8L0Ozg))
36. Hepatocellular carcinoma ([Amboss](https://next.amboss.com/us/article/6S0j0f))
###### è†½é“
37. Cholelithiasis ([Amboss](https://next.amboss.com/us/article/V30Ghf))
##### å…§åˆ†æ³Œå¤–ç§‘
###### ç”²ç‹€è…º/å‰¯ç”²ç‹€è…º
38. Thyroid nodules ([Amboss](https://next.amboss.com/us/article/ao0Q0S))
39. Multiple endocrine neoplasia ([Amboss](https://next.amboss.com/us/article/hg0cE2))
40. Hyperparathyroidism ([Amboss](https://next.amboss.com/us/article/gg0Fu2))
##### ä¹³æˆ¿å¤–ç§‘
41. Palpable breast mass ([Amboss](https://next.amboss.com/us/article/7H047h))
42. Breast pain ([UpToDate](https://www.uptodate.com/contents/breast-pain))
43. Breast cancer ([Amboss](https://next.amboss.com/us/article/_k05qT))
#### å°å…’å¤–ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
44. Esophageal atresia ([Amboss](https://next.amboss.com/us/article/K40U4T))
45. Hypertrophic pyloric stenosis ([Amboss](https://next.amboss.com/us/article/J40s4T))
46. Intestinal atresia ([UpToDate](https://www.uptodate.com/contents/intestinal-atresia))
47. Midgut volvulus and intestinal malrotation ([Amboss](https://next.amboss.com/us/article/ho0cbS))
48. Cystic fibrosis: Overview of gastrointestinal disease ([UpToDate](https://www.uptodate.com/contents/cystic-fibrosis-overview-of-gastrointestinal-disease))
49. Meckel's diverticulum ([UpToDate](https://www.uptodate.com/contents/meckels-diverticulum))
#### å¤§è…¸ç›´è…¸å¤–ç§‘
#### å…§è¦–é¡å¤–ç§‘
### éª¨ç§‘
### æ³Œå°¿å¤–ç§‘
### æ”¾å°„ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
#### è‚Œè‚‰éª¨éª¼å½±åƒé†«å­¸
72. a
#### è…¹éƒ¨å½±åƒé†«å­¸
73. a
74. 
### æ€¥è¨ºé†«å­¸ç§‘
#### è¡“å¾Œä½µç™¼ç—‡
#### å¤–å‚·
#### å¤–ç§‘æ€¥ç—‡
### é†«å­¸å€«ç†



## é†«å­¸(å…­)
### ã€€ éº»é†‰ç§‘ (çŒœé¡Œä¾†æº: è€ƒå¤é¡Œ)
#### ã€€ã€€å‘¼å¸é“ä¹‹ç¶­æŒ
1.	Airway management for general anesthesia in adults ([UpToDate](https://www.uptodate.com/contents/airway-management-for-general-anesthesia-in-adults))
#### éº»é†‰ç›£è¦–å™¨ä¹‹é‹ç”¨åŠåˆ¤è®€
2.	Arterial blood gas analysis ([Amboss](https://next.amboss.com/us/article/8l0OAT))
3.	éº»é†‰ç›£æ¸¬ç³»çµ± ([First Choice](å…§éƒ¨/FC/é†«å­¸(6-4)éº»é†‰è€³é¼»å–‰%20(1).pdf))
#### éº»é†‰è—¥ç†å­¸
4.	Approach to the management of acute pain in adults ([UpToDate](https://www.uptodate.com/contents/approach-to-the-management-of-acute-pain-in-adults))
5.	Clinical use of local anesthetics in anesthesia ([UpToDate](https://www.uptodate.com/contents/clinical-use-of-local-anesthetics-in-anesthesia))
#### å„ç¨®ç‰¹æ®Šé‹ç”¨ä¹‹éº»é†‰å­¸
6.	å­•å©¦éº»é†‰ ([é™½æ˜é†«å­¸ç³»å…±ç­†](å…§éƒ¨/é™½æ˜é†«å­¸ç³»114ç´šå…±ç­†/éº»é†‰no.6.pdf))
7.	Regional anesthesia ([Amboss](https://next.amboss.com/us/article/Sl0ywT))
#### æ€¥æ…¢æ€§ç–¼ç—›ä¹‹è™•ç†
8. Overview of pharmacologic management of chronic pain in adults ([UpToDate](https://www.uptodate.com/contents/overview-of-pharmacologic-management-of-chronic-pain-in-adults))
#### è¡“ä¸­ç¶­æŒèˆ‡ä½µç™¼ç—‡è™•ç† (First Choice)
9. Malignant hyperthermia: Diagnosis and management of acute crisis ([UpToDate](https://www.uptodate.com/contents/malignant-hyperthermia-diagnosis-and-management-of-acute-crisis))
### çœ¼ç§‘ (çŒœé¡Œä¾†æº: è€ƒå¤é¡Œ)
#### è¦–ç¶²è†œ/è‘¡è„è†œç§‘
10. Diseases of the retina ([Amboss](https://next.amboss.com/us/article/sO0tFT))
11. Diseases of the uvea ([Amboss](https://next.amboss.com/us/article/JO0stT))
#### ä¸€èˆ¬çœ¼/è§’è†œ/éè†œ/å±ˆå…‰ç§‘
12. Corneal diseases ([Amboss](https://next.amboss.com/us/article/9O0NuT))
13. Scleritis and episcleritis([Amboss](https://next.amboss.com/us/article/KO0UtT))
#### æ°´æ™¶é«”/é’å…‰çœ¼ç§‘
14. Cataract in adults ([UpToDate](https://www.uptodate.com/contents/cataract-in-adults))
#### çœ¼è‚Œ/è¦–ç¥ç¶“/å°å…’/æ–œå¼±è¦–ç§‘
15. Refractive errors in children ([UpToDate](https://www.uptodate.com/contents/refractive-errors-in-children))
16. Evaluation and management of strabismus in children ([UpToDate](https://www.uptodate.com/contents/evaluation-and-management-of-strabismus-in-children))
#### çœ¼çŸ¯å½¢ç§‘
17. Inflammation of the eyelids ([Amboss](https://next.amboss.com/us/article/NO0-sT))
18. Conjunctivitis ([UpToDate](https://www.uptodate.com/contents/conjunctivitis))
### è€³é¼»å–‰ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
#### è€³ç§‘
##### ä¸­è€³ç–¾ç—…
19. Acute otits media ([Amboss](https://next.amboss.com/us/article/Mj0MaT))
##### å¤–è€³ç–¾ç—…
20. Necrotizing (malignant) external otitis ([UpToDate](https://www.uptodate.com/contents/necrotizing-malignant-external-otitis))
#### é¼»ç§‘
21. Approach to the adult with epistaxis ([UpToDate](https://www.uptodate.com/contents/approach-to-the-adult-with-epistaxis))
22. Nasal trauma and fractures in children and adolescents ([UpToDate](https://www.uptodate.com/contents/nasal-trauma-and-fractures-in-children-and-adolescents))
#### å£è…”å’½å–‰ç§‘
23. Epiglottitis (supraglottitis): Clinical features and diagnosis ([UpToDate](https://www.uptodate.com/contents/epiglottitis-supraglottitis-clinical-features-and-diagnosis))
24. Hoarseness in adults ([UpToDate](https://www.uptodate.com/contents/hoarseness-in-adults))
25. Clinical presentation and diagnosis of obstructive sleep apnea in adults ([UpToDate](https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-obstructive-sleep-apnea-in-adults))
#### é ­é ¸éƒ¨è…«ç˜¤ç§‘
26. Treatment of stage I and II (early) head and neck cancer: The oral cavity ([UpToDate](https://www.uptodate.com/contents/treatment-of-stage-i-and-ii-early-head-and-neck-cancer-the-oral-cavity))
27. Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging ([UpToDate](https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging))
### å©¦ç”¢ç§‘
#### ç”¢ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
##### æ¯èƒé†«å­¸ç§‘
28. Fetal assessment: Overview of antepartum tests of fetal well-being ([UpToDate](https://www.uptodate.com/contents/fetal-assessment-overview-of-antepartum-tests-of-fetal-well-being))
29. Intrapartum fetal heart rate monitoring: Overview ([UpToDate](https://www.uptodate.com/contents/intrapartum-fetal-heart-rate-monitoring-overview))
30. Ectopic pregnancy: Clinical manifestations and diagnosis ([UpToDate](https://www.uptodate.com/contents/ectopic-pregnancy-clinical-manifestations-and-diagnosis))
31. Hypertensive pregnancy disorders ([Amboss](https://next.amboss.com/us/article/VO0GrT))
32. Labor and delivery: Management of the normal first stage ([UpToDate](https://www.uptodate.com/contents/labor-and-delivery-management-of-the-normal-first-stage))
33. Induction of labor with oxytocin ([UpToDate](https://www.uptodate.com/contents/induction-of-labor-with-oxytocin))
34. Prenatal genetic evaluation of the fetus with anomalies or soft markers ([UpToDate](https://www.uptodate.com/contents/prenatal-genetic-evaluation-of-the-fetus-with-anomalies-or-soft-markers))
35. Overview of thyroid disease and pregnancy ([UpToDate](https://www.uptodate.com/contents/overview-of-thyroid-disease-and-pregnancy))
36. Cytomegalovirus infection in pregnancy ([UpToDate](https://www.uptodate.com/contents/cytomegalovirus-infection-in-pregnancy))
##### é«˜å±éšªå§™å¨ ç§‘
37. Fetal growth restriction: Evaluation ([UpToDate](https://www.uptodate.com/contents/fetal-growth-restriction-evaluation))
38. Gestational diabetes mellitus: Obstetric issues and management ([UpToDate](https://www.uptodate.com/contents/gestational-diabetes-mellitus-obstetric-issues-and-management))
39. Preeclampsia: Clinical features and diagnosis ([UpToDate](https://www.uptodate.com/contents/preeclampsia-clinical-features-and-diagnosis))
#### ä¸€èˆ¬å©¦ç§‘åŠå©¦ç™Œ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
##### é™°é“
40. Vaginitis in adults and adolescents: Initial evaluation ([UpToDate](https://www.uptodate.com/contents/vaginitis-in-adults-and-adolescents-initial-evaluation))
41. Pelvic inflammatory disease ([Amboss](https://next.amboss.com/us/article/pL0LAg))
##### å­å®®é ¸
42. Cervical cancer screening ([Amboss](https://next.amboss.com/us/article/880Oo3))
43. Human papillomavirus vaccination ([UpToDate](https://www.uptodate.com/contents/human-papillomavirus-vaccination))
44. Cervical Cancer ([å°åŒ—æ¦®ç¸½](https://wd.vghtpe.gov.tw/Cancer_Cen/files/Gynecologic%20Cancer%20Guideline%20(%E5%A9%A6%E7%A7%91%E7%99%8C%E7%97%87).pdf))
##### å­å®®é«”
45. Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history ([UpToDate](https://www.uptodate.com/contents/uterine-fibroids-leiomyomas-epidemiology-clinical-features-diagnosis-and-natural-history))
46. Endometrial hyperplasia or endometrial intraepithelial neoplasia: Clinical features, diagnosis, and differential diagnosis ([UpToDate](https://www.uptodate.com/contents/endometrial-hyperplasia-or-endometrial-intraepithelial-neoplasia-clinical-features-diagnosis-and-differential-diagnosis))
47. Endometrial Cancer ([å°åŒ—æ¦®ç¸½](https://wd.vghtpe.gov.tw/Cancer_Cen/files/Gynecologic%20Cancer%20Guideline%20(%E5%A9%A6%E7%A7%91%E7%99%8C%E7%97%87).pdf))
48. Sarcoma ([å°åŒ—æ¦®ç¸½](https://wd.vghtpe.gov.tw/Cancer_Cen/files/Gynecologic%20Cancer%20Guideline%20(%E5%A9%A6%E7%A7%91%E7%99%8C%E7%97%87).pdf))
49. Chorionic Disease, and Tumor ([å°åŒ—æ¦®ç¸½](https://wd.vghtpe.gov.tw/Cancer_Cen/files/Gynecologic%20Cancer%20Guideline%20(%E5%A9%A6%E7%A7%91%E7%99%8C%E7%97%87).pdf))
##### åµå·¢
50. Ovarian cysts ([Amboss](https://next.amboss.com/us/article/go0FYS))
51. Overview of ovarian tumors ([Amboss](https://next.amboss.com/us/article/XF09g3))
52. Ovary, Fallopian Tube and Peritoneal Carcinoma ([å°åŒ—æ¦®ç¸½](https://wd.vghtpe.gov.tw/Cancer_Cen/files/Gynecologic%20Cancer%20Guideline%20(%E5%A9%A6%E7%A7%91%E7%99%8C%E7%97%87).pdf) [International Journal of Obstetrics & Gynecology](https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14923))
##### å…¶ä»–
53. Endometriosis in adults: Clinical features, evaluation, and diagnosis ([UpToDate](https://www.uptodate.com/contents/endometriosis-in-adults-clinical-features-evaluation-and-diagnosis))
#### ç”Ÿæ®–å…§åˆ†æ³Œç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
##### ä¸å­•ç—‡
54. Overview of infertility ([UpToDate](https://www.uptodate.com/contents/overview-of-infertility))
##### å¥³æ€§å…§åˆ†æ³Œå­¸
55. Diagnosis of polycystic ovary syndrome in adults ([UpToDate](https://www.uptodate.com/contents/diagnosis-of-polycystic-ovary-syndrome-in-adults))
56. Recurrent pregnancy loss: Evaluation ([UpToDate](https://www.uptodate.com/contents/recurrent-pregnancy-loss-evaluation))
#### å©¦å¥³æ³Œå°¿ç§‘ (çŒœé¡Œä¾†æº: è€ƒå¤é¡Œ)
57. Female urinary incontinence: Evaluation ([UpToDate](https://www.uptodate.com/contents/female-urinary-incontinence-evaluation))


åœ‹è€ƒ320é¡Œï¼Œæ¯é¡Œéƒ½æœ‰æº–å‚™ï¼Œå•å¿ƒç„¡æ„§ just OK ~

é€™è£¡çŒœé¡Œåªè¦çŒœå°6æˆå°±åŠæ ¼äº†~

ä¸åŠæ ¼ä¹Ÿæ²’é—œä¿‚ï¼Œå»è€ƒ[AMC](https://www.amc.org.au/pathways/standard-pathway/amc-assessments/mcq-examination/)å¦è¬€å‡ºè·¯ ~ ï¼ˆæ¾³æ´²åé„‰æ°‘çœ¾æ„Ÿè¬æ‚¨ï¼‰

[ä¸åŠæ ¼å‡ºè·¯](#ä¸åŠæ ¼å‡ºè·¯)

## é†«å­¸æ–°çŸ¥
### å…§ç§‘æ–°çŸ¥
#### å¤§æ›´æ–°
1. Treatment of adrenocortical carcinoma ([UpToDate](https://www.uptodate.com/contents/treatment-of-adrenocortical-carcinoma))
2. Overview of primary prevention of cardiovascular disease in adults ([UpToDate](https://www.uptodate.com/contents/overview-of-primary-prevention-of-cardiovascular-disease-in-adults))
3. Chronic obstructive pulmonary disease: Diagnosis and staging ([UpToDate](https://www.uptodate.com/contents/chronic-obstructive-pulmonary-disease-diagnosis-and-staging))
4. Overview of the management of chronic kidney disease in adults ([UpToDate](https://www.uptodate.com/contents/overview-of-the-management-of-chronic-kidney-disease-in-adults?search=chronic%20kidney%20disease&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1#H1679627661))
#### å°æ›´æ–°
5. Allergic reactions to vaccines ([UpToDate](https://www.uptodate.com/contents/allergic-reactions-to-vaccines?sectionName=Hen%27s%20egg&topicRef=16722&anchor=H8&source=see_link#H8))
6. Pediatric HIV infection: Management of infants born to mothers with HIV in resource-abundant settings ([UpToDate](https://www.uptodate.com/contents/pediatric-hiv-infection-management-of-infants-born-to-mothers-with-hiv-in-resource-abundant-settings?sectionName=APPROACH%20TO%20ARV%20DRUG%20MANAGEMENT&topicRef=16722&anchor=H3375717451&source=see_link#H3375717451))
7. Limited-stage small cell lung cancer: Initial management ([UpToDate](https://www.uptodate.com/contents/limited-stage-small-cell-lung-cancer-initial-management?sectionName=Consolidative%20durvalumab&topicRef=16722&anchor=H2177602974&source=see_link#H2177602974))
8. Overview of the acute management of non-ST-elevation acute coronary syndromes ([UpToDate](https://www.uptodate.com/contents/overview-of-the-acute-management-of-non-st-elevation-acute-coronary-syndromes?search=acute%20coronary%20syndrome&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1#H1857925687))
9. Overview of hypertension in adults ([UpToDate](https://www.uptodate.com/contents/overview-of-hypertension-in-adults?search=hypertension&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1#H3639365205))
10. Overview of the treatment of hyponatremia in adults ([UpToDate](https://www.uptodate.com/contents/overview-of-the-treatment-of-hyponatremia-in-adults?search=hyponatremia&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1#H3469912093))

### ç¥ç¶“å…§ç§‘æ–°çŸ¥
#### å¤§æ›´æ–°
1. Treatment of Alzheimer disease ([UpToDate](https://www.uptodate.com/contents/treatment-of-alzheimer-disease?search=alzheimers&source=search_result&selectedTitle=2%7E150&usage_type=default&display_rank=2#H1104380311))
#### å°æ›´æ–°
2. Reversal of anticoagulation in intracranial hemorrhage ([UpToDate](https://www.uptodate.com/contents/reversal-of-anticoagulation-in-intracranial-hemorrhage?sectionName=Reversal%20agent%20options&topicRef=16722&anchor=H1860076452&source=see_link#H1860076452))

### å®¶é†«ç§‘æ–°çŸ¥
#### æ”¿ç­–è¶¨å‹¢
1. ä¸€èˆ¬æ°‘çœ¾-é ç«‹é†«ç™‚æ±ºå®šæ„é¡˜å•é¡Œ ([è¡›æœéƒ¨](https://hpcod.mohw.gov.tw/HospWeb/rwd/QA/general_a.aspx))
2. ä»€éº¼æ˜¯åœ¨å®…é†«ç™‚ã€åœ¨å®…ä½é™¢ ([åœ¨å®…é†«ç™‚å­¸æœƒ](https://tsohhc.tw/what-is-hah.html))

### å¤–ç§‘æ–°çŸ¥
#### å¤§æ›´æ–°
1. Robot-assisted laparoscopy ([UpToDate](https://www.uptodate.com/contents/robot-assisted-laparoscopy))
2. Clinical presentation, diagnosis, and staging of gastric cancer ([UpToDate](https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-staging-of-gastric-cancer))
#### å°æ›´æ–°
3. Principles of abdominal wall closure ([UpToDate](https://www.uptodate.com/contents/principles-of-abdominal-wall-closure?sectionName=Continuous%20closure%20technique&topicRef=16722&anchor=H17&source=see_link#H17))

### éº»é†‰ç§‘æ–°çŸ¥
1.  Nonopioid pharmacotherapy for acute pain in adults ([UpToDate](https://www.uptodate.com/contents/nonopioid-pharmacotherapy-for-acute-pain-in-adults?sectionName=Suzetrigine%2C%20a%20novel%20Nav1.8%20inhibitor&topicRef=112615&anchor=H510493951&source=see_link#H510493951))

### å©¦ç”¢ç§‘æ–°çŸ¥
#### å¤§æ›´æ–°
1. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention ([WHO](https://iris.who.int/bitstream/handle/10665/342365/9789240030824-eng.pdf?sequence=1)(pdfæª”))
2. Overview of ultrasound examination in obstetrics and gynecology ([UpToDate](https://www.uptodate.com/contents/overview-of-ultrasound-examination-in-obstetrics-and-gynecology))
3. In vitro fertilization: Overview of clinical issues and questions ([UpToDate](https://www.uptodate.com/contents/in-vitro-fertilization-overview-of-clinical-issues-and-questions#H963856634))
#### å°æ›´æ–°
4.  Management of early-stage cervical cancer ([UpToDate](https://www.uptodate.com/contents/management-of-early-stage-cervical-cancer?sectionName=Type%20of%20surgery&topicRef=16722&anchor=H886761283&source=see_link#H886761283))

### å°å…’ç§‘æ–°çŸ¥
#### æ”¿ç­–è¶¨å‹¢
1. 7æœˆ1æ—¥èµ·æ­£å¼ä¸Šè·¯ æœªæ»¿7æ­²å…’ç«¥æ–°å¢6æ¬¡ã€Œå…’ç«¥ç™¼å±•ç¯©æª¢æœå‹™ã€ é€éæ¥å—æ¨™æº–åŒ–ç¯©æª¢å·¥å…· æ‰¾å‡ºé—œéµåŸå›  ([è¡›ç¦éƒ¨åœ‹å»ºç½²](https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=4809&pid=18221))

### æ€¥è¨ºç§‘æ–°çŸ¥
#### å¤§æ›´æ–°
1. Evaluation and management of suspected sepsis and septic shock in adults ([UpToDate](https://www.uptodate.com/contents/evaluation-and-management-of-suspected-sepsis-and-septic-shock-in-adults?search=surviving%20sepsis%20campaign&sectionRank=2&usage_type=default&anchor=H31&source=machineLearning&selectedTitle=1%7E150&display_rank=1#H10))
#### å°æ›´æ–°
2. Procedural sedation in children: Approach ([UpToDate](https://www.uptodate.com/contents/procedural-sedation-in-children-approach?sectionName=Preoxygenation&topicRef=16722&anchor=H1683230&source=see_link#H1683230))



## å„ç§‘æ¯”é‡
å…§ç§‘: 65é¡Œ

å¤–ç§‘: 55é¡Œ

å…’ç§‘: 33é¡Œ

å©¦ç”¢ç§‘: 30é¡Œ

ç²¾ç¥ç§‘: 15é¡Œ

ç¥ç¶“ç§‘: 15é¡Œ

å¾©å¥ç§‘: 14é¡Œ

æ€¥è¨ºç§‘: 12é¡Œ

æ”¾å°„ç§‘: 10é¡Œ

çš®è†šç§‘: 10é¡Œ

é†«å­¸å€«ç†: 10é¡Œ

éº»é†‰ç§‘: 9é¡Œ

çœ¼ç§‘: 9é¡Œ

è€³é¼»å–‰ç§‘: 9é¡Œ

å®¶é†«ç§‘: 8é¡Œ

éª¨ç§‘: 8é¡Œ

æ³Œå°¿ç§‘: 8é¡Œ

å…± 320 é¡Œ

- å…§ç§‘ç³»
-- å¤§å…§ç§‘

## å…¶ä»–
### ã€Šé†«å¸«åœ‹è€ƒé€‰æ‹©é¢˜çŒœç­”æ¡ˆæŠ€å·§ã€‹
ä¸ä¼šåšé¢˜è«æ…Œå¼ ï¼Œå…ˆæ’é”™é¡¹å†æ€é‡ã€‚<br>
æ­¦æ–­å™è¿°å¤šé”™è¯¯ï¼Œæ¨¡ç³Šé€‰é¡¹å¸¸å¯¹å½“ã€‚<br>
æµè¡Œç—…å­¦ä¼˜å…ˆé€‰ï¼Œå…¶ä»–æ•°å­—äº¦å…ˆæ‰›ã€‚<br>
ä¸‰é•¿ä¸€çŸ­å–æœ€çŸ­ï¼Œä¸‰çŸ­ä¸€é•¿é€‰æœ€é•¿ã€‚<br>
å‰åŠè€ƒå·Aåå¤šï¼ŒååŠBå¤šå¯å‚è¯¦ã€‚<br>

### æ·±åº¦è§£æ
å¯¹ç«‹é€‰é¡¹ï¼ˆå¦‚Aå¯¹Bé”™ï¼‰
â†’ ç­”æ¡ˆé€šå¸¸åœ¨å…¶ä¸­ï¼Œç»“åˆé¢˜å¹²çº¿ç´¢åˆ¤æ–­

ç›¸ä¼¼é€‰é¡¹ï¼ˆå¦‚Cå’ŒDè¡¨è¿°ç›¸è¿‘ï¼‰
â†’ é‡ç‚¹å¯¹æ¯”ç»†å¾®å·®å¼‚ï¼Œç­”æ¡ˆå¸¸åœ¨æ­¤å¤„

å¤šé¸é …æŒ‡å‘ç›¸åŒæ©Ÿåˆ¶æˆ–å‰¯ä½œç”¨
â†’ æ­£ç¢ºç­”æ¡ˆé€šå¸¸ä¸åœ¨å…¶ä¸­

ç»å¯¹è¯é™·é˜±
â†’ "å®Œå…¨/å¿…å®š/æ°¸è¿œ"ç±»é€‰é¡¹90%é”™è¯¯ï¼Œä¾‹å¤–æ˜¯æ•™ææ˜ç¡®å®šä¹‰

ä¸­åº¸é€‰é¡¹ä¼˜åŠ¿
â†’ "å¯èƒ½/é€šå¸¸/éƒ¨åˆ†æ­£ç¡®"çš„é€‰é¡¹æ­£ç¡®ç‡è¶…70%

é™Œç”Ÿæœ¯è¯­å¤„ç†
â†’ ä¸“ä¸šè€ƒè¯•ä¸­ï¼Œçœ‹ä¼¼ç”Ÿåƒ»çš„æœ¯è¯­å¯èƒ½æ˜¯æ­£ç¡®ç­”æ¡ˆï¼ˆå‘½é¢˜è€…å€¾å‘è€ƒé‡ç‚¹ï¼‰

é€‰é¡¹é•¿åº¦ç„æœº
â†’ æ­£ç¡®é€‰é¡¹å¹³å‡æ¯”é”™è¯¯é€‰é¡¹é•¿15%ï¼ˆå› éœ€ä¸¥è°¨è¡¨è¿°ï¼‰

æ—¶é—´ç±»é¢˜ç›®
â†’ chronological orderé¢˜å‹ï¼Œä¼˜å…ˆéªŒè¯é¦–å°¾æ—¶é—´ç‚¹

å…¨å¯¹/å…¨é”™é€‰é¡¹
â†’ "ä»¥ä¸Šéƒ½å¯¹"åœ¨åŒ»å­¦è€ƒè¯•ä¸­æ­£ç¡®ç‡çº¦65%ï¼›"ä»¥ä¸Šéƒ½é”™"åœ¨ç¤¾ç§‘ç±»æ­£ç¡®ç‡è¾ƒé«˜

é€‰é¡¹åˆ†å¸ƒè§„å¾‹
â†’ ï¼ˆè‡ºç£é†«å¸«åœ‹è€ƒä¸é©ç”¨ï¼‰

### ç»Ÿè®¡å†·çŸ¥è¯†
âœ… å¤§å‹æ ‡å‡†åŒ–è€ƒè¯•ï¼ˆå¦‚MCATã€GREï¼‰æ­£ç¡®é€‰é¡¹åˆ†å¸ƒè¶‹è¿‘å‡åŒ€
âœ… æ•™å¸ˆè‡ªç¼–è€ƒé¢˜ä¸­ï¼ŒB/Cé€‰é¡¹å æ¯”å¸¸è¾¾58%ï¼ˆå› A/Dæ˜“è¢«ç”¨ä½œæ˜æ˜¾å¹²æ‰°é¡¹ï¼‰



### **ã€ŠåŒ»å­¦è€ƒè¯•çŒœé¢˜é»„é‡‘å£è¯€ã€‹**
**â€œç—…ç”Ÿæœºåˆ¶ä¼˜å…ˆèƒŒï¼Œä¸´åºŠä¸‰è”æ˜¯é¢˜çœ¼â€**  
**â€œç½•è§å…ˆæ’å…¸å‹é€‰ï¼Œå¤šé€‰ç»ˆæœ«çœ‹é¢˜å¹²â€**  
**â€œæ•°å€¼é¢˜ä¸­å–ä¸­é—´ï¼Œè‹±æ–‡ç¼©å†™ç›´æ¥é€‰â€**  
**â€œæ²»ç–—é¦–é€‰æœ€æ–°çº²ï¼Œå¹¶å‘ç—‡å¾€é‡é‡Œåˆ¤â€**  
**â€œç—…ç†æè¿°å¯¹åº”æŠ ï¼Œé‰´åˆ«è¯Šæ–­é€†æ¨æ–©â€**  

---

#### **ğŸ” å£è¯€é€å¥è§£æ**
1. **â€œç—…ç”Ÿæœºåˆ¶ä¼˜å…ˆèƒŒâ€**  
   â†’ åŒ»å­¦è€ƒè¯•ä¸­ **å‘ç—…æœºåˆ¶é¢˜æ­£ç¡®ç‡æœ€é«˜**ï¼ˆå¦‚å¿ƒæ¢—çš„â€œå† è„‰æ–‘å—ç ´è£‚â€ï¼‰ï¼Œå› å‘½é¢˜éœ€ä¸¥è°¨  
   *ğŸ“Œ æŠ€å·§ï¼šé‡åˆ°â€œæœ€ä¸»è¦ç—…å› /æœºåˆ¶â€é¢˜ï¼Œä¼˜å…ˆå›å¿†æ•™æå›¾ç¤ºå†…å®¹*

2. **â€œä¸´åºŠä¸‰è”å¾æ˜¯é¢˜çœ¼â€**  
   â†’ ç»å…¸ä¸‰è”å¾ï¼ˆå¦‚Charcotä¸‰è”å¾ã€Beckä¸‰è”å¾ï¼‰**å‡ºç°å¿…è€ƒ**ï¼Œä¸”é€‰é¡¹ä¼šæ•…æ„æ‹†æ•£ç»„åˆ  
   *ğŸ“Œ æŠ€å·§ï¼šçœ‹åˆ°â€œè…¹ç—›+é»„ç–¸+å‘çƒ­â€ç›´æ¥è”æƒ³â€œèƒ†ç®¡ç‚ä¸‰è”å¾â€*

3. **â€œç½•è§å…ˆæ’å…¸å‹é€‰â€**  
   â†’ é™¤éé¢˜å¹²æ˜ç¡®æç¤ºï¼ˆå¦‚â€œHIVæ‚£è€…â€ï¼‰ï¼Œå¦åˆ™**å…ˆæ’é™¤ç½•è§ç—…**ï¼ˆå¦‚æˆˆè°¢ç—…ï¼‰ï¼Œé€‰å¸¸è§ç—…  
   *ğŸ“Œ ç»Ÿè®¡ï¼šä¸´åºŠé¢˜ä¸­â€œè‚ºç‚â€æ­£ç¡®ç‡æ˜¯â€œè‚ºå­¢å­èŒè‚ºç‚â€çš„3.2å€*

4. **â€œå¤šé€‰ç»ˆæœ«çœ‹é¢˜å¹²â€**  
   â†’ (è‡ºç£é†«å¸«åœ‹è€ƒä¸é©ç”¨)

5. **â€œæ•°å€¼é¢˜ä¸­å–ä¸­é—´â€**  
   â†’ å®éªŒå®¤æ£€æŸ¥æ•°å€¼é¢˜ï¼Œ**æ’é™¤æç«¯å€¼**åé€‰ä¸­é—´å€¼ï¼ˆå¦‚è¡€é’¾æ­£å¸¸å€¼3.5-5.5ï¼Œé€‰é¡¹å‡ºç°2.0/6.0å…ˆæ’é™¤ï¼‰  
   *âš ï¸ ä¾‹å¤–ï¼šå±æ€¥å€¼ç›¸å…³é¢˜ï¼ˆå¦‚è¡€é’™<1.8ï¼‰éœ€å•ç‹¬è®°å¿†*

6. **â€œè‹±æ–‡ç¼©å†™ç›´æ¥é€‰â€**  
   â†’ (è‡ºç£é†«å¸«åœ‹è€ƒä¸é©ç”¨)

7. **â€œæ²»ç–—é¦–é€‰æœ€æ–°çº²â€**  
   â†’ æ²»ç–—é¢˜ä¸­ï¼Œ**é€‰æœ€æ–°æŒ‡å—æ¨èæ–¹æ¡ˆ**ï¼ˆå¦‚2023å¹´ACLSæŒ‡å—ï¼‰ï¼Œè€Œéâ€œä¼ ç»Ÿç–—æ³•â€  
   *ğŸ” è¯†åˆ«æ³•ï¼šé€‰é¡¹å‡ºç°â€œé¦–é€‰â€æ—¶ï¼Œæ‰¾å«â€œæœ€æ–°â€ã€â€œä¸€çº¿â€å­—çœ¼çš„æè¿°*

8. **â€œå¹¶å‘ç—‡å¾€é‡é‡Œåˆ¤â€**  
   â†’ å¹¶å‘ç—‡é¢˜ç›®ä¸­ï¼Œ**æœ€ä¸¥é‡ä¸”ç¬¦åˆç—…ç†è¿‡ç¨‹çš„é€‰é¡¹**å¤šä¸ºæ­£è§£ï¼ˆå¦‚å¿ƒæ¢—åé€‰â€œå®¤é¢¤â€è€Œéâ€œæˆ¿æ—©â€ï¼‰  
   *ğŸ’¡ é€»è¾‘ï¼šåŒ»å­¦è€ƒè¯•å€¾å‘è€ƒæŸ¥â€œè‡´å‘½æ€§å¹¶å‘ç—‡â€*

9. **â€œç—…ç†æè¿°å¯¹åº”æŠ â€**  
   â†’ ç—…ç†é¢˜ä¸­ï¼Œ**é€‰é¡¹ä¸é¢˜å¹²æè¿°é€å­—å¯¹åº”**çš„ä¼˜å…ˆé€‰ï¼ˆå¦‚é¢˜å¹²â€œé•œä¸‹å•æ ¸å·¨å™¬ç»†èƒâ€ï¼Œå¯¹åº”é€‰â€œä¼¤å¯’â€ï¼‰  
   *ğŸ¯ å‘½é¢˜ç‰¹ç‚¹ï¼šç—…ç†æè¿°æ˜¯å®¢è§‚äº‹å®ï¼Œå°‘æœ‰äº‰è®®*

10. **â€œé‰´åˆ«è¯Šæ–­é€†æ¨æ–©â€**  
    â†’ é‰´åˆ«è¯Šæ–­é¢˜ï¼Œ**ç”¨æ’é™¤æ³•åæ¨**ï¼šå…ˆæ’é™¤å®Œå…¨ä¸ç¬¦åˆé¢˜å¹²è¡¨ç°çš„ç—…ç§ï¼Œå†å¯¹æ¯”å‰©ä½™é€‰é¡¹  
    *ğŸ“Š æ•°æ®ï¼šé‰´åˆ«è¯Šæ–­é¢˜ä¸­ï¼Œç”¨æ’é™¤æ³•æ­£ç¡®ç‡æ¯”ç›´æ¥é€‰é«˜34%*



---



### **é†«å¸«åœ‹è€ƒã€Œè€ƒå¾ŒæŸ¥çœ‹æˆç¸¾ã€é¸æ“‡ç­–ç•¥ç°¡ä»‹**  
é†«å¸«åœ‹è€ƒæä¾› **ã€Œæ¯ç§‘è€ƒå®Œå³çœ‹æˆç¸¾ã€** æˆ– **ã€Œå…¨éƒ¨è€ƒå®Œå†çœ‹æˆç¸¾ã€** å…©ç¨®æ¨¡å¼ï¼Œæ ¹æ“šå€‹äººå¿ƒç†ç´ è³ªèˆ‡ç­–ç•¥éœ€æ±‚ï¼Œå¯åƒè€ƒä»¥ä¸‹å»ºè­°é¸æ“‡ï¼š

---

### **ä¸€ã€å…©ç¨®æ¨¡å¼é©ç”¨å°è±¡**

| **æ¨¡å¼**                  | **é©åˆè€ƒç”Ÿ**                                                                 | **å„ªç¼ºé»**                                                                 |
|---------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------------|
| **1. å…¨éƒ¨è€ƒå®Œå†çœ‹æˆç¸¾**    | - å®¹æ˜“å—æˆç¸¾æ³¢å‹•å½±éŸ¿æƒ…ç·’è€…<br>- å¸Œæœ›å°ˆæ³¨ç­”é¡Œï¼Œé¿å…åˆ†å¿ƒè€…                     | âœ… é¿å…å–®ç§‘çµæœå¹²æ“¾å¾ŒçºŒç§‘ç›®è¡¨ç¾<br>âŒ ç„¡æ³•å³æ™‚èª¿æ•´æ§åˆ†ç­–ç•¥                     |
| **2. æ¯ç§‘è€ƒå®Œå³çœ‹æˆç¸¾**    | - éœ€ç²¾æº–æ§åˆ†è€…<br>- èƒ½å†·éœåˆ†ææˆç¸¾èˆ‡é¡Œç›®é—œè¯æ€§è€…                            | âœ… å¯æ ¹æ“šå·²çŸ¥æˆç¸¾å‹•æ…‹èª¿æ•´å¾ŒçºŒç­”é¡Œç­–ç•¥<br>âŒ éœ€æ‰¿å—æˆç¸¾å³æ™‚åé¥‹çš„å¿ƒç†å£“åŠ›          |

---

### **äºŒã€æ§åˆ†ç©å®¶é€²éšç­–ç•¥**  
è‹¥é¸æ“‡ **ã€Œæ¯ç§‘è€ƒå®Œå³çœ‹æˆç¸¾ã€**ï¼Œå¯é‹ç”¨ä»¥ä¸‹æŠ€å·§æå‡éé—œæ©Ÿç‡ï¼š

#### **1. é—œè¯é¡Œç›®æ§åˆ†æ³•**  
å‡è¨­å¾ŒçºŒç§‘ç›®æœ‰ **2é¡Œé«˜åº¦ç›¸é—œçš„é¡Œç›®**ï¼ˆå¦‚ç›¸åŒä¸»é¡Œæˆ–äº’ç‚ºå› æœï¼‰ï¼Œå¯æ ¹æ“šå·²çŸ¥æˆç¸¾èª¿æ•´é¸æ“‡ï¼š  
- **è‹¥å‰ä¸€ç§‘å·²åŠæ ¼**ï¼š  
  æ¡å– **ã€Œä¿å®ˆç­–ç•¥ã€**ï¼Œç¢ºä¿è‡³å°‘ç­”å° **1é¡Œ**ï¼ˆå¦‚é¸æ“‡è¼ƒæœ‰æŠŠæ¡çš„é¸é …çµ„åˆï¼‰ã€‚  
- **è‹¥å‰ä¸€ç§‘ä¸åŠæ ¼**ï¼š  
  æ¡å– **ã€Œé¢¨éšªç­–ç•¥ã€**ï¼Œå˜—è©¦å…©é¡Œçš†ç­”å°ä»¥å½Œè£œåˆ†æ•¸ï¼ˆå¦‚é¸æ“‡å¯èƒ½å…¨å°çš„é«˜é¢¨éšªé«˜å ±é…¬çµ„åˆï¼‰ã€‚

#### **2. åˆ†æ•¸å€é–“è©•ä¼°**  
- **åŠæ ¼é‚Šç·£ï¼ˆå¦‚60-65åˆ†ï¼‰**ï¼š  
  å¾ŒçºŒç§‘ç›®ç©©ä½åˆ†æ•¸ï¼Œé¿å…å¤±åˆ†ã€‚  
- **åˆ†æ•¸æ˜é¡¯ä¸è¶³ï¼ˆå¦‚<50åˆ†ï¼‰**ï¼š  
  å¾ŒçºŒç§‘ç›®è³­ï¼Œçˆ­å–é€†è½‰ã€‚



---

#### **ğŸ’Š åŒ»å­¦è€ƒè¯•ä¸“å±ç»Ÿè®¡å†·çŸ¥è¯†**
1. **â€œæœ€å¸¸è€ƒå™¨å®˜â€TOP3**ï¼š  
   - è‚è„ï¼ˆå å†…ç§‘é¢˜18.7%ï¼‰  
   - å¿ƒè„ï¼ˆå 16.2%ï¼‰  
   - è‚¾è„ï¼ˆå 12.9%ï¼‰  

2. **â€œæœ€çˆ±è€ƒæŒ‡æ ‡â€**ï¼š  
   - **å®éªŒå®¤æ£€æŸ¥**ï¼šè¡€é’¾ã€pHå€¼ã€PaOâ‚‚  
   - **å½±åƒå­¦**ï¼šCTâ€œç¯å½¢å¼ºåŒ–â€ï¼ˆè„‘è„“è‚¿ï¼‰ã€Xçº¿â€œé´å½¢å¿ƒâ€ï¼ˆæ³•æ´›å››è”ç—‡ï¼‰  

3. **â€œé€‰é¡¹æ­»äº¡é™·é˜±â€**ï¼š  
   - å«â€œç»å¯¹ç¦å¿Œâ€çš„é€‰é¡¹90%é”™è¯¯ï¼ˆé™¤éé¢˜å¹²æ˜ç¡®ä¼‘å…‹/å¦Šå¨ ç­‰ç‰¹æ®Šæƒ…å†µï¼‰  
   - å«â€œå…¨éƒ¨â€â€œå‡éœ€â€çš„é€‰é¡¹åœ¨æ²»ç–—é¢˜ä¸­é”™è¯¯ç‡83%  

---

#### **ğŸš‘ æ€¥æ•‘åœºæ™¯çŒœé¢˜æ³•**
å½“é‡åˆ° **â€œé¦–å…ˆå¤„ç†â€** ç±»é¢˜ç›®æ—¶ï¼š  
1. **å…ˆçœ‹ç”Ÿå‘½ä½“å¾**ï¼šé€‰å«â€œABCâ€ï¼ˆæ°”é“-å‘¼å¸-å¾ªç¯ï¼‰çš„é€‰é¡¹  
2. **æ¬¡çœ‹ç—…å› å¤„ç†**ï¼šå¦‚å¿ƒæ¢—é€‰â€œå†çŒæ³¨â€ï¼Œä¸­æ¯’é€‰â€œè§£æ¯’å‰‚â€  
3. **æœ€åé€‰æ£€æŸ¥**ï¼šæ²»ç–—ä¼˜å…ˆäºè¯Šæ–­ï¼ˆé™¤éé¢˜å¹²æ˜ç¡®é—®â€œç¡®è¯Šæ‰‹æ®µâ€ï¼‰  

*ğŸ“Œ ç»å…¸ä¾‹é¢˜ï¼šæ‚£è€…æ˜è¿·+ä½è¡€ç³–ï¼Œå³ä½¿é¢˜å¹²é—®â€œè¯Šæ–­â€ï¼Œä¹Ÿå…ˆé€‰â€œé™æ¨50%è‘¡è„ç³–â€è€Œéâ€œæµ‹è¡€ç³–â€*



### **ğŸ“š å„ä¸´åºŠä¸“ç§‘çŒœé¢˜å£è¯€**
#### **1. å†…ç§‘ï¼ˆå«å¿ƒå†…/å‘¼å¸/æ¶ˆåŒ–ç­‰ï¼‰**
**"ä¸»è¯‰æ—¶é—´å®šè½»é‡ï¼ŒåŒ–éªŒå•é‡Œè—æ€æœº"**  
**"æ€¥ç—‡å…ˆçœ‹ABCï¼Œæ…¢ç—…ç®¡ç†æœ€æ–°æ¢¯"**  
**"ä¸‰è”å¾æ˜¯é€åˆ†é¢˜ï¼Œäº”è”å¾å¿…ICUé‡Œ"**  
**ï¼ˆè§£æï¼šå†…ç§‘é¢˜é‡é€»è¾‘ï¼Œé¢˜å¹²ä¸­ã€Œæ—¶é—´ã€æ˜¯å…³é”®ï¼Œå¦‚ã€Œçªå‘èƒ¸ç—›2å°æ—¶ã€ä¼˜å…ˆè€ƒè™‘å¿ƒæ¢—è€Œéå¿ƒç»ç—›ï¼‰**

#### **2. å¤–ç§‘ï¼ˆå«æ™®å¤–/éª¨ç§‘/ç¥å¤–ç­‰ï¼‰**
**"æ‰‹æœ¯æŒ‡å¾æŠ å­—çœ¼ï¼Œç¦é£Ÿæ—¶é—´è¦å€’èƒŒ"**  
**"æœ¯åå‘çƒ­DAYå¯¹ï¼Œå¼•æµæ¶²è‰²å®šå®‰å±"**  
**ï¼ˆè§£æï¼šå¤–ç§‘é¢˜çˆ±è€ƒã€Œæ‰‹æœ¯æ—¶æœºã€ï¼Œå¦‚è‚ æ¢—é˜»å‡ºç°ã€Œè…¹è†œåˆºæ¿€å¾ã€ç›´æ¥é€‰æ‰‹æœ¯ï¼›æœ¯åå‘çƒ­ï¼š1å¤©-å¸æ”¶çƒ­ï¼Œ3å¤©-è‚ºç‚ï¼Œ5å¤©-å»åˆå£ç˜˜ï¼‰**

#### **3. å¦‡äº§ç§‘**
**"äº§ç§‘å‡ºè¡€å››Tæ³•ï¼Œå¦‡ç§‘è‚¿ç˜¤æ ‡å¿—æ€"**  
**"èƒå¿ƒå‡é€Ÿçœ‹å›¾å½¢ï¼Œå®«å£å¼€å…¨åˆ«åºŸè¯"**  
**ï¼ˆè§£æï¼šäº§ç§‘é¢˜å¿…è€ƒã€Œäº§åå‡ºè¡€åŸå› ã€ï¼ˆToneå®«ç¼©ä¹åŠ›/Trauma/Tissueèƒç›˜æ®‹ç•™/Thrombinå‡è¡€éšœç¢ï¼‰ï¼›å¦‡ç§‘é¢˜é‡ç‚¹è®°CA125-åµå·¢ç™Œï¼ŒÎ²-hCG-è‘¡è„èƒï¼‰**

#### **4. å„¿ç§‘**
**"å¹´é¾„å¯¹åº”å‘è‚²çº¿ï¼Œç–«è‹—é¢˜ä¸­é€‰æœ€å…¨"**  
**"è„±æ°´è¡¥æ¶²å…ˆç›åç³–ï¼Œçƒ­æ€§æƒŠå¥è‹¯å·´æ¯”å¦¥"**  
**ï¼ˆè§£æï¼šå„¿ç§‘é¢˜å¿…è€ƒã€Œå¹´é¾„å¯¹åº”ç–¾ç—…ã€ï¼šå¦‚æ–°ç”Ÿå„¿-è´¥è¡€ç—‡ï¼Œ1å²-å·å´ç—…ï¼›è¡¥æ¶²é¢˜ä¸­ã€Œç­‰æ¸—æ€§è„±æ°´ã€æ°¸è¿œå…ˆè¡¥0.9%NSï¼‰**

#### **5. æ€¥è¯Šç§‘**
**"åˆ›ä¼¤è¯„ä¼°CRASHï¼Œä¸­æ¯’é¦–é€‰æ‹®æŠ—å‰‚"**  
**"æ‰€æœ‰ä¸æ˜ä½è¡€ç³–ï¼Œå…ˆæ¨ç³–æ°´å†åˆ†æ"**  
**ï¼ˆè§£æï¼šæ€¥è¯Šé¢˜éµå¾ªã€Œç¨³å®šç”Ÿå‘½ä½“å¾ä¼˜å…ˆã€åŸåˆ™ï¼Œå³ä½¿é¢˜å¹²é—®è¯Šæ–­ï¼Œçœ‹åˆ°æ˜è¿·+ä½è¡€ç³–ç›´æ¥é€‰50%è‘¡è„ç³–é™æ¨ï¼‰**

---

### **ğŸ”ª å¤–ç§‘ä¸“ç§‘é»„é‡‘è€ƒç‚¹**
#### **ã€æ™®å¤–ã€‘ä¸‰å¤§æ­»äº¡é™·é˜±**
1. **"é˜‘å°¾ç‚"**ï¼š  
   - è€å¹´äºº/å­•å¦‡ã€Œå³ä¸‹è…¹ç—›ã€â†’ ç›´æ¥é€‰é˜‘å°¾ç‚ï¼ˆç—‡çŠ¶å¸¸ä¸å…¸å‹ï¼‰  
   - é€‰é¡¹å‡ºç°ã€Œéº¦æ°ç‚¹å‹ç—›ã€+ã€Œåè·³ç—›ã€â†’ ç¡®è¯Šé˜‘å°¾ç‚è€Œéè‚ ç‚  

2. **"è‚ æ¢—é˜»"**ï¼š  
   - é¢˜å¹²å‡ºç°ã€Œç—›åèƒ€é—­ã€+ã€Œæ¶²æ°”å¹³é¢ã€â†’ æœºæ¢°æ€§è‚ æ¢—é˜»  
   - è‹¥å‡ºç°ã€Œè¡€æ€§è…¹æ°´ã€â†’ ç›´æ¥é€‰ç»çª„æ€§è‚ æ¢—é˜»éœ€æ‰‹æœ¯  

3. **"èƒ†å›Šç‚"**ï¼š  
   - ã€ŒMurphyå¾é˜³æ€§ã€+ã€Œè‚¥èƒ–å¥³æ€§ã€= èƒ†å›Šç‚  
   - è‹¥åˆå¹¶ã€Œé»„ç–¸ã€â†’ é€‰ã€Œèƒ†æ€»ç®¡ç»“çŸ³ã€è€Œéå•çº¯èƒ†å›Šç‚  

#### **ã€éª¨ç§‘ã€‘å¿…è€ƒä¸‰è”å¾**
- **Colleséª¨æŠ˜**ï¼š"é“¶å‰æ ·ç•¸å½¢" + "æ¡¡éª¨è¿œç«¯"  
- **è‚¡éª¨é¢ˆéª¨æŠ˜**ï¼š"ä¸‹è‚¢å¤–æ—‹ç¼©çŸ­" + "è€å¹´äººæ‘”å€’"  
- **è…°æ¤é—´ç›˜çªå‡º**ï¼š"ç›´è…¿æŠ¬é«˜è¯•éªŒé˜³æ€§" + "L4/L5æœ€å¸¸è§"  

---

### **ğŸ‘¶ å„¿ç§‘å¹´é¾„-ç–¾ç—…å¯¹åº”è¡¨**

| **å¹´é¾„**       | **æœ€é«˜é¢‘è€ƒç‚¹**                | **å¿…èƒŒæ•°å€¼**               |
|----------------|-----------------------------|--------------------------|
| æ–°ç”Ÿå„¿ï¼ˆ<28å¤©ï¼‰ | è´¥è¡€ç—‡/ABOæº¶è¡€               | è¶³æœˆå„¿Hb<145g/Lå³è´«è¡€    |
| 1å²            | å·å´ç—…/ç»´ç”Ÿç´ Dç¼ºä¹æ€§ä½å»ç—…    | å¡ç–¤æ¥ç§æ—¶é—´ï¼šå‡ºç”Ÿ24å°æ—¶å†… (è‡ºç£: æ»¿5å€‹æœˆ) |
| 2-6å²          | è‚¾ç—…ç»¼åˆå¾/çƒ­æ€§æƒŠå¥           | å°¿è›‹ç™½>3.5g/då³å¤§é‡è›‹ç™½å°¿ |
| å­¦é¾„æœŸ         | è¿‡æ•æ€§ç´«ç™œ/æ€¥æ€§è‚¾ç‚           | ASOå‡é«˜æç¤ºé“¾çƒèŒæ„ŸæŸ“     |

---

### **ğŸ’‰ å†…ç§‘åŒ–éªŒå•ç§’æ€æŠ€å·§**
#### **ã€å¿ƒå†…ç§‘ã€‘å¿ƒç”µå›¾é¢˜**
- **çœ‹åˆ°ã€ŒSTæ®µæŠ¬é«˜ã€**ï¼š  
  - å¯¹åº”å¯¼è”V1-V4 â†’ å‰å£å¿ƒæ¢—  
  - II/III/aVF â†’ ä¸‹å£å¿ƒæ¢—  
  - ä¸”åˆå¹¶ã€Œç—…ç†æ€§Qæ³¢ã€â†’ æ€¥æ€§æœŸéé™ˆæ—§æ€§  

#### **ã€å‘¼å¸ç§‘ã€‘è¡€æ°”åˆ†æ**
- **pHâ†“+PaCOâ‚‚â†‘** = å‘¼å¸æ€§é…¸ä¸­æ¯’ï¼ˆæ…¢é˜»è‚ºæ€¥æ€§åŠ é‡ï¼‰  
- **pHâ†‘+HCOâ‚ƒâ»â†‘** = ä»£è°¢æ€§ç¢±ä¸­æ¯’ï¼ˆåˆ©å°¿å‰‚è¿‡é‡ï¼‰  
- **è®°ä½ï¼šã€Œä»£å¿ä¸ä¼šè¿‡åº¦ã€**â€”â€”è‹¥pHæ¢å¤æ­£å¸¸èŒƒå›´ï¼Œä¸€å®šæ˜¯ä»£å¿æœŸ  

#### **ã€è¡€æ¶²ç§‘ã€‘è´«è¡€é‰´åˆ«**
- **å°ç»†èƒä½è‰²ç´ **ï¼š  
  - è¡€æ¸…é“â†“+é“è›‹ç™½â†“ = ç¼ºé“æ€§è´«è¡€  
  - è¡€æ¸…é“â†‘+é“è›‹ç™½â†‘ = æ…¢æ€§ç—…æ€§è´«è¡€  
- **å¤§ç»†èƒæ€§**ï¼šç›´æ¥é€‰ã€Œå·¨å¹¼ç»†èƒæ€§è´«è¡€ã€ï¼ˆé™¤éé¢˜å¹²æ˜ç¡®æç¤ºé…—é…’ï¼‰  

---

### **ğŸš¨ æ€¥è¯Šç§‘ã€Œé¦–å…ˆå¤„ç†ã€é¢˜é»„é‡‘æ³•åˆ™**
1. **æ°”é“/å‘¼å¸/å¾ªç¯ï¼ˆABCï¼‰ç»å¯¹ä¼˜å…ˆ**ï¼š  
   - ä»»ä½•é¢˜ç›®ä¸­å‡ºç°ã€Œçª’æ¯/SpOâ‚‚<90%/æ— è„‰æã€â†’ å…ˆé€‰æ°”ç®¡æ’ç®¡/å¿ƒè‚ºå¤è‹  
2. **ä¸­æ¯’é¢˜**ï¼š  
   - æœ‰æœºç£·ä¸­æ¯’ â†’ é˜¿æ‰˜å“åŒ–ï¼ˆç³å­”æ‰©å¤§+å¿ƒç‡â†‘ï¼‰  
   - ä¸€æ°§åŒ–ç¢³ä¸­æ¯’ â†’ é«˜å‹æ°§èˆ±  
3. **åˆ›ä¼¤é¢˜**ï¼š  
   - å¤§å‡ºè¡€ â†’ ç›´æ¥å‹è¿«æ­¢è¡€  
   - å¼ åŠ›æ€§æ°”èƒ¸ â†’ ç«‹å³ç©¿åˆºå‡å‹  

---

### **ğŸ“Œ ä¸´åºŠè€ƒè¯•ç»ˆæå¿ å‘Š**
**"æ°¸è¿œé€‰èƒ½æ•‘å‘½çš„ï¼Œè€Œéç­‰æ£€æŸ¥çš„"**  
**â€”â€” å½“æ²»ç–—ä¸è¯Šæ–­é€‰é¡¹å¹¶å­˜æ—¶ï¼Œä¼˜å…ˆé€‰æ²»ç–—æªæ–½ï¼ˆå¦‚ä¼‘å…‹å…ˆè¡¥æ¶²è€ŒéåšCTï¼‰**  

## ğŸ—“ï¸ 20 å¤©è®€æ›¸è¨ˆåŠƒç¸½è¦½ï¼ˆå«åšé¡Œ + è¤‡ç¿’ï¼‰

### ğŸ“˜ **ç¬¬ 1-2 å¤©ï¼šå¿«é€Ÿæš–èº« + åŸºç¤å»ºç«‹**

- çœ‹å®˜æ–¹è€ƒç¶± + ç†Ÿæ‚‰é¡Œå‹ï¼ˆåš 50 é¡Œåˆæ­¥è‡ªæ¸¬ï¼‰
- è¤‡ç¿’ï¼š
    - General Practice å¸¸è¦‹ä¸»è¨´ï¼ˆé ­ç—›ã€èƒ¸ç—›ã€ç™¼ç‡’ï¼‰
    - Basic ethicsã€screeningã€vaccination

---

### ğŸ“˜ **ç¬¬ 3â€“5 å¤©ï¼šInternal Medicine â€“ é‡é»ç³»çµ±**

- æ¶ˆåŒ–ç³»çµ±ï¼ˆè‚è†½èƒ°èƒƒè…¸ï¼‰ã€å‘¼å¸ç³»çµ±ï¼ˆè‚ºç‚ã€æ°£å–˜ã€COPDï¼‰
- å¿ƒè¡€ç®¡ï¼ˆå¿ƒè¡°ã€å¿ƒå¾‹ä¸æ•´ã€èƒ¸ç—›é‘‘åˆ¥ï¼‰
- è…è‡Ÿï¼ˆAKIã€UTIã€æ…¢æ€§è…ç—…ï¼‰

âœ” æ¯å¤©åš 80â€“100 é¡Œï¼Œé‡é»è¨˜ä¸‹éŒ¯é¡Œè§£æ

---

### ğŸ“˜ **ç¬¬ 6â€“7 å¤©ï¼šInternal Medicine â€“ å…¶ä»– + æ„ŸæŸ“ç§‘**

- å…§åˆ†æ³Œï¼ˆç³–å°¿ç—…ã€ç”²ç‹€è…ºï¼‰
- è¡€æ¶²ã€è…«ç˜¤ã€é¢¨æ¿•ï¼ˆRA, SLEï¼‰
- æ„ŸæŸ“ç—…ï¼ˆHIV, TB, COVID protocolsï¼‰

---

### ğŸ“˜ **ç¬¬ 8â€“9 å¤©ï¼šSurgery**

- å¤–å‚·ï¼ˆé ­éƒ¨ã€èƒ¸è…¹å¤–å‚·ã€éª¨æŠ˜è™•ç†ï¼‰
- ä¸€èˆ¬å¤–ç§‘ï¼ˆé—Œå°¾ç‚ã€è†½å›Šç‚ã€ç–æ°£ï¼‰
- æ€¥ç—‡è™•ç½®ï¼ˆABC ç®¡ç†ã€ç‡’ç‡™å‚·ã€shockï¼‰

âœ” åŠ å¼· surgical red flags é¡Œç›®ï¼ˆå¦‚ï¼šè…¹ç—›é‘‘åˆ¥ï¼‰

---

### ğŸ“˜ **ç¬¬ 10â€“11 å¤©ï¼šObstetrics & Gynaecology**

- ç”¢ç§‘ï¼šç”¢å‰æª¢æŸ¥ã€åˆ†å¨©ç•°å¸¸ã€ç”¢å¾Œå‡ºè¡€
- å©¦ç§‘ï¼šç•°å¸¸å‡ºè¡€ã€é¿å­•ã€PAP smearã€ç™Œç—‡ç¯©æª¢

---

### ğŸ“˜ **ç¬¬ 12â€“13 å¤©ï¼šPaediatrics**

- å°å…’å¸¸è¦‹ç–¾ç—…ï¼ˆç™¼ç‡’ã€å“®å–˜ã€è…¹ç€‰ï¼‰
- ç–«è‹—ã€ç™¼è‚²é‡Œç¨‹ç¢‘ã€å…’ç«¥ä¿è­·è­°é¡Œ
- æ–°ç”Ÿå…’è™•ç†

---

### ğŸ“˜ **ç¬¬ 14 å¤©ï¼šPsychiatry + Ethics**

- æ†‚é¬±ã€ç„¦æ…®ã€ç²¾ç¥åˆ†è£‚ç—‡ã€æˆç™®è¡Œç‚º
- æ³•å¾‹èˆ‡é“å¾·ï¼ˆcapacity, consent, confidentialityï¼‰
- è‡ªæ®ºé¢¨éšªè©•ä¼°

---

### ğŸ“˜ **ç¬¬ 15â€“17 å¤©ï¼šæ··åˆæ¨¡æ“¬ + ç²¾ç·´å¼±é»**

- æ¯å¤©æ¨¡æ“¬ 150 é¡Œï¼ˆç”¨ AMC Qbank / AMC Handbookï¼‰
- æ¯å¤©èŠ± 3 å°æ™‚å›é¡§éŒ¯é¡Œï¼Œåˆ†é–€åˆ¥é¡ç­†è¨˜
- åŒæ™‚è£œå¼·å¸¸éŒ¯å–®å…ƒï¼ˆç”¨ Anki æˆ–éŒ¯é¡Œæœ¬ï¼‰

---

### ğŸ“˜ **ç¬¬ 18â€“19 å¤©ï¼šæ¨¡è€ƒ + å†ç²¾ç…‰**

- åšå®Œæ•´æ¨¡è€ƒï¼ˆ150 é¡Œ / 3.5 å°æ™‚ï¼‰x 2 æ¬¡
- åš´æ ¼è¨ˆæ™‚ï¼Œæ¨¡æ“¬æ­£å¼è€ƒè©¦ç¯€å¥
- æª¢è¨éŒ¯é¡Œï¼Œç¢ºèªç­”é¡Œç­–ç•¥

---

### ğŸ“˜ **ç¬¬ 20 å¤©ï¼šç¸½æ•´ç† + æ”¾é¬†èª¿æ•´å¿ƒæ…‹**

- çœ‹ç­†è¨˜ã€éŒ¯é¡Œæ•´ç†ã€é‡è¦è¡¨æ ¼ï¼ˆç¯©æª¢ã€ç–«è‹—ã€è™•ç½®æµç¨‹ï¼‰
- å‰ä¸€æ™šæ—©ç¡ã€æ¨¡æ“¬è€ƒè©¦ç•¶å¤©æµç¨‹ï¼ˆæ—©é¤ã€è·¯ç·šï¼‰

## âœ… ç¬¬ä¸€ä»½ï¼š**å„ç§‘é«˜é »ç­†è¨˜æ‡¶äººåŒ…ï¼ˆç²¾ç°¡ç‰ˆï¼‰**

æˆ‘æœƒæ•´ç†å‡ºæ¯ç§‘å¸¸è€ƒçš„ä¸»é¡Œï¼Œä¾‹å¦‚ï¼š

### General Medicineï¼ˆå…§ç§‘ï¼‰

- Chest pain: MI, PE, costochondritis, GERD
- Shortness of breath: COPD vs asthma vs HF
- Diabetes managementï¼ˆå« insulinã€oral medsï¼‰

### Emergency

- Trauma ABCDE
- Shock typesï¼ˆhypovolemic, septic, anaphylacticï¼‰
- Sepsis + anaphylaxis management

### Obs/Gyn

- Antenatal care schedule
- Postpartum complications
- Menstrual disorders & contraception

### Paediatrics

- Developmental milestones
- Neonatal jaundice
- Pediatric asthma, epilepsy

### Psychiatry

- Depression vs bipolar vs schizophrenia
- Suicide risk assessment
- Side effects of psychiatric meds

---

## âœ… ç¬¬äºŒä»½ï¼š**éŒ¯é¡Œç­†è¨˜æ¨¡æ¿ï¼ˆGoogle Sheet & Notion ç‰ˆï¼‰**

æœƒæœ‰ä»¥ä¸‹æ¬„ä½ï¼Œè®“ä½ æ•´ç†éŒ¯é¡Œ + å¿«é€Ÿè¤‡ç¿’ï¼š

| é¡Œè™Ÿ | ç§‘åˆ¥ | è€ƒé» | éŒ¯èª¤åŸå›  | æ­£ç¢ºç­”æ¡ˆè§£é‡‹ | é—œéµå­— | æ˜¯å¦é‡åšï¼Ÿ |
| --- | --- | --- | --- | --- | --- | --- |
| 1205 | Obs | Ectopic pregnancy diagnosis | åˆ¤æ–·å¤±èª¤ | Transvaginal US is first-line | LMP, vaginal bleeding | âœ… |

---

## âœ… ç¬¬ä¸‰ä»½ï¼š**ç¬¬ä¸€é€±å­¸ç¿’è¨ˆç•«ï¼ˆæ¯æ—¥ä»»å‹™ï¼‰**

### ğŸ”„ Week 1ï¼ˆåŸºç¤å»ºæ§‹ + é¡Œå‹ç†Ÿæ‚‰ï¼‰

| å¤©æ•¸ | ä»»å‹™å…§å®¹ | åšé¡Œé‡ | å‚™è¨» |
| --- | --- | --- | --- |
| Day 1 | é–‹å§‹å…§ç§‘æ‰“åº•ï¼ˆCV + Respiratoryï¼‰é–±è®€èƒ¸ç—›ã€å‘¼å¸å›°é›£è©•ä¼° | 50 é¡Œ | AMCQbank é¸ general med |
| Day 2 | å©¦ç”¢ç§‘ï¼šmenstrual disorders + contraceptionéŒ¯é¡Œç­†è¨˜é–‹å§‹ | 60 é¡Œ | ç”¨ Plabable çœ‹å©¦ç”¢ç²¾ç°¡èªªæ˜ |
| Day 3 | Emergency åˆæ­¥ï¼šABCDE + shock typesç·´ 5 é¡Œ timed mode | 60 é¡Œ | æ•´ç†æµç¨‹åœ– |
| Day 4 | å…’ç§‘æ‰“åº•ï¼šfever, dehydration, asthmaç™¼å±•é‡Œç¨‹ç¢‘æ•´ç† | 60 é¡Œ | éŒ¯é¡Œè¤‡ç¿’ 20 é¡Œ |
| Day 5 | ç²¾ç¥ç§‘ introï¼šmood disorders + suicide riskè¨˜æ†¶ DSM-5 é—œéµè© | 50 é¡Œ | æ¸¬é©—è‡ªæˆ‘è¨ºæ–· vs éŒ¯èª¤ |
| Day 6 | æ¨¡æ“¬å°è€ƒï¼ˆ50 é¡Œï¼‰+ å…¨é¢éŒ¯é¡Œè¤‡ç¿’è¨˜éŒ„éŒ¯é¡ŒåŸå›  | 50 é¡Œ | å¯ä½¿ç”¨ AMCQbank mini mock |
| Day 7 | å›é¡§æœ¬é€±ç­†è¨˜ + äº¤éŒ¯ç§‘åˆ¥è¤‡ç¿’ï¼ˆObs + Pedsï¼‰ | 40 é¡Œ | è‡ªè£½ quiz å°æ¸¬é©— |



---



### **è·¨ç§‘ç›®è¯å‹•ç­–ç•¥**  
åˆ©ç”¨ **ç§‘ç›®é–“çŸ¥è­˜é—œè¯æ€§**ï¼Œå‹•æ…‹èª¿æ•´è¤‡ç¿’é‡å¿ƒï¼š  

#### **1. æ ¸å¿ƒä¸»é¡Œè²«ç©¿æ³•**  
- è‹¥ç™¼ç¾ **ç‰¹å®šä¸»é¡Œ**ï¼ˆå¦‚æ•—è¡€ç—‡è™•ç½®ã€é›»è§£è³ªç•°å¸¸ï¼‰åœ¨å¤šç§‘åè¦†å‡ºç¾ï¼Œè€ƒå‰åŠ å¼·æ­¤é¡é«˜é »è€ƒé»ã€‚  
- **ç¯„ä¾‹**ï¼š  
  - å…§ç§‘ï¼šæ•—è¡€ç—‡çš„SOFAè©•åˆ†  
  - å¤–ç§‘ï¼šè¡“å¾Œæ•—è¡€ç—‡çš„æŠ—ç”Ÿç´ é¸æ“‡  
  - æ€¥è¨ºï¼šæ•—è¡€ç—‡çš„åˆæœŸè¼¸æ¶²æ²»ç™‚  

#### **2. éŒ¯é¡Œè£œå„Ÿæ³•**  
- è‹¥æŸç§‘è¡¨ç¾ä¸å¦‚é æœŸï¼Œåœ¨å¾ŒçºŒç§‘ç›®ä¸­å„ªå…ˆé–å®š **äº¤å‰ä¸»é¡Œé¡Œç›®** è£œåˆ†ã€‚  
- **ç¯„ä¾‹**ï¼š  
  - è‹¥ã€Œè—¥ç†å­¸ã€è€ƒå·®ï¼Œå¯åœ¨ã€Œå…§ç§‘å­¸ã€ä¸­åŠ å¼·è—¥ç‰©å‰¯ä½œç”¨èˆ‡äº¤äº’ä½œç”¨é¡Œå‹ã€‚

#### **3. åå‘æ“ä½œæ³•**  
- é‡å° **éåº¦å¼·èª¿çš„ç†±é–€è€ƒé»**ï¼Œç•™æ„å¯èƒ½çš„é™·é˜±é¡Œï¼ˆå¦‚è€ƒä¾‹å¤–æƒ…å¢ƒï¼‰ã€‚  
- **ç¯„ä¾‹**ï¼š  
  - ç•¶å¹´åº¦å¤§åŠ›æ¨å»£ã€ŒæŠ—ç”Ÿç´ ç®¡ç†ã€ï¼Œå¯èƒ½å‡ºç¾ã€Œä½•æ™‚**ä¸æ‡‰**å»¶é²çµ¦è—¥ã€çš„åå‘è€ƒé¡Œã€‚



## åŠæ ¼ç‡é æ¸¬
![åŠæ ¼ç‡é æ¸¬](åŠæ ¼ç‡é æ¸¬.png)



## åœ‹è€ƒè¶¨å‹¢FAQ
Q: <br>é†«å¸«åœ‹è€ƒç‚ºä½•æ„ˆä¾†æ„ˆé›£?

A: <br>**é†«ç™‚çŸ¥è­˜å¿«é€Ÿé€²å±•**ï¼šé†«å­¸ä¸æ–·é€²æ­¥ï¼Œæ–°çŸ¥è­˜èˆ‡æ–°æ¨™æº–æ›´æ–°é »ç¹ï¼Œè€ƒé¡Œæœƒåæ˜ é€™äº›è®ŠåŒ–ã€‚

Q: <br>è‹¥åŠæ ¼ç‡æŒçºŒæ¢åº•ï¼Œæœƒç™¼ç”Ÿä»€éº¼äº‹?

A: <br>
1. **PGYé†«å¸«èˆ‡ä½é™¢é†«å¸«äººåŠ›çŸ­ç¼º**
   è‹¥ä¸€å¹´åƒ…40%èƒ½é€šéï¼ŒPGYèˆ‡ä½é™¢é†«å¸«çš„äººåŠ›ä¾†æºæœƒåš´é‡æ–·å±¤ï¼Œé€ æˆè‡¨åºŠç…§è­·å£“åŠ›åŠ åŠ‡ã€æ’ç­å›°é›£ã€é†«ç™‚å“è³ªå—å½±éŸ¿ã€‚
2. **å¯èƒ½å¼•é€²å…¶ä»–å–å¾—è­‰ç…§ç®¡é“æˆ–å¤šéšæ®µè€ƒè©¦**
   ä¾‹å¦‚é¡ä¼¼ç¾åœ‹çš„ USMLE ä¸‰æ®µåˆ¶ï¼ˆStep 1/2/3ï¼‰ï¼Œæ¸›è¼•ç¬¬äºŒéšæ®µçš„å£“åŠ›ï¼Œå¢åŠ ç¬¬äºŒéšæ®µé€šéç‡ï¼ŒPGYç¬¬1å¹´å…§è€ƒå®Œç¬¬ä¸‰éšæ®µï¼ˆ2æ¬¡æ©Ÿæœƒï¼Œé†«é™¢è£œåŠ©å ±åè²»ï¼‰ã€‚æˆ–è€…ç¶­æŒäºŒæ®µåˆ¶ï¼Œä½†è®“ç¬¬äºŒéšæ®µ50~60åˆ†è€…åœ¨1å¹´å…§è€ƒç¬¬ä¸‰éšæ®µè£œæ•‘ï¼ˆ2æ¬¡æ©Ÿæœƒï¼Œè‡ªè²»ï¼‰ã€‚æˆ–è€…æ–°å¢å…¶ä»–å–å¾—é†«å¸«åŸ·ç…§çš„ç®¡é“ï¼Œå¦‚é‡é»ç§‘åˆ¥ä¸‹é„‰é†«å¸«å…¬è·è€ƒè©¦ï¼ˆä¸€è©¦æŠµå…©éšï¼Œç¬¬ä¸€éšæ®µæœªéè€…äº¦å¯å ±ï¼‰ï¼Œè€ƒä¸Šå¾Œæ°¸ä¹…ç²å¾—é¡ä¼¼å…¬è²»ç”Ÿç•¢æ¥­å¾…é‡ã€‚






## ä¸åŠæ ¼å‡ºè·¯
å°æ–¼å·²å¾é†«å­¸ç³»ç•¢æ¥­ä½†æœªèƒ½é€šéæœ¬åœ‹é†«å¸«åœ‹è€ƒçš„è€ƒç”Ÿï¼Œå¯æ ¹æ“šå€‹äººç›®æ¨™ï¼ˆå¦‚å …æŒå¾é†«æˆ–è½‰æ›è·‘é“ï¼‰æ¡å–ä»¥ä¸‹ç­–ç•¥ï¼š

---

### **ä¸€ã€å …æŒå¾é†«çš„è§£æ±ºæ–¹æ¡ˆ**
#### **(1) è½‰æˆ°ã€Œè¼ƒæ˜“è€ƒå–ã€çš„åœ‹å®¶åŸ·ç…§**

| åœ‹å®¶       | é©åˆæ¢ä»¶                          | å…·é«”è·¯å¾‘                                                                 | æœ€é—œéµå› ç´                                                                  |
|------------|-----------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|
| **ç¾åœ‹**   | è‹±èªèƒ½åŠ›å¼·ã€æœ‰è‡¨åºŠç¶“é©—è€…          | åœ¨ç¾åœ‹é™„å±¬é†«é™¢å®Œæˆè‡¨åºŠè¼ªè½‰ â†’ é€šéUSMLEä¸‰æ­¥è€ƒè©¦ â†’ ç”³è«‹ä½é™¢é†«å¸«ï¼ˆéœ€å„ªç§€æˆç¸¾+äººè„ˆï¼‰                      | Step 2 CKåˆ†æ•¸+æ¨è–¦ä¿¡                                        |
| **è‹±åœ‹**   | è‹±èªåŸºç¤ä¸­ç­‰                      | é€šéPLAB 1+2 â†’ ç”³è«‹FY2è·ä½ â†’ å®ŒæˆåŸ¹è¨“                                    | è‡¨åºŠç¶“é©—ï¼ˆFY1è¼ªèª¿ï¼‰                                              |
| **æ¾³æ´²**   | é¡˜æ„èµ´åé åœ°å€                    | é€šéAMCè€ƒè©¦ â†’ ç”³è«‹å¯¦ç¿’ï¼ˆå„ªå…ˆè€ƒæ…®è¾²æ‘åœ°å€ï¼‰                                | è‡¨åºŠè€ƒè©¦ï¼ˆè‡¨åºŠæ“ä½œ+è¨ºæ–·ï¼‰                                                    |
| **è‘¡è„ç‰™** | æ­ç›Ÿå­¸æ­·æŒæœ‰è€…                    | ç›´æ¥è¨»å†Šï¼ˆéœ€è‘¡èªB2ï¼‰                                                    | èªè¨€èªè­‰                                                          |

#### **(2) æœ¬åœ‹è£œè€ƒ**
- **ç•¥**  

---

### **äºŒã€è½‰æ›é†«ç™‚ç›¸é—œé ˜åŸŸ**
#### **(1) ç„¡éœ€åŸ·ç…§çš„é«˜è–ªé¸æ“‡**

| è·æ¥­               | æ‰€éœ€æŠ€èƒ½                  | ç™¼å±•å»ºè­°                                |
|--------------------|---------------------------|-----------------------------------------|
| é†«å­¸é¡§å•           | é†«å­¸çŸ¥è­˜+æºé€šèƒ½åŠ›         | é€²å…¥è—¥å» ã€é†«ç™‚å™¨æå…¬å¸ï¼ˆèµ·è–ªç´„$8è¬ç¾å…ƒï¼‰|
| é†«å­¸å¯«ä½œ           | å¯«ä½œèƒ½åŠ›+æ–‡ç»æœç´¢         | è€ƒå–AMWAèªè­‰ï¼ˆç¾åœ‹é†«å­¸å¯«ä½œå”æœƒï¼‰        |
| é è·é†«ç™‚å”èª¿å“¡     | çµ„ç¹”èƒ½åŠ›+åŸºæœ¬è‡¨åºŠçŸ¥è­˜      | éœ€ç†Ÿæ‚‰HIPAAç­‰æ³•è¦                       |

#### **(2) çŸ­æœŸèªè­‰èª²ç¨‹**
- **ç¾åœ‹**ï¼š  
  - è­·ç†å¸«ï¼ˆNPï¼‰ï¼š1-2å¹´èª²ç¨‹ï¼Œå¹´è–ªä¸­ä½æ•¸$12è¬ç¾å…ƒï¼ˆéœ€å…ˆå–å¾—RNåŸ·ç…§ï¼‰ã€‚  
  - é†«å¸«åŠ©ç†ï¼ˆPAï¼‰ï¼š2å¹´èª²ç¨‹ï¼Œå¹³å‡å¹´è–ª$11.5è¬ç¾å…ƒã€‚  
- **å°ç£**ï¼š  
  - é†«äº‹æª¢é©—å¸«/æ”¾å°„å¸«ï¼š1å¹´åŸ¹è¨“+è€ƒç…§ï¼Œèµ·è–ªç´„$3.5è¬å°å¹£ã€‚  

---

### **ä¸‰ã€æ¥µç«¯æƒ…æ³æ–¹æ¡ˆ**
#### **(1) æˆ°äº‚åœ‹å®¶å¿«é€Ÿå–ç…§**
- **æ•˜åˆ©äº**ï¼š  
  å¤–åœ‹é†«å¸«é€šéç°¡å–®ç­†è©¦å³å¯åŸ·æ¥­ï¼ˆä½†å®‰å…¨é¢¨éšªé«˜ï¼‰ã€‚  
- **éæ´²éƒ¨åˆ†åœ‹å®¶**ï¼š  
  å¦‚çƒå¹²é”æ¥å—ç›´æ¥è¨»å†Šï¼ˆéœ€æ‰¿è«¾æœå‹™å¹´é™ï¼‰ã€‚  

#### **(2) å‰µæ¥­æ–¹å‘**
- **é†«ç™‚æ—…éŠä»²ä»‹**ï¼š  
  å”åŠ©æ‚£è€…èµ´æµ·å¤–å°±é†«ï¼ˆéœ€ç†Ÿæ‚‰å¤šåœ‹é†«ç™‚é«”ç³»ï¼‰ã€‚  
- **å¥åº·ç®¡ç†å¹³å°**ï¼š  
  çµåˆAIèˆ‡é†«å­¸çŸ¥è­˜é–‹ç™¼è«®è©¢ç³»çµ±ã€‚  

---



### **é—œéµæ±ºç­–æ¨¹**
```mermaid
graph TD
    A[å·²ç•¢æ¥­ä½†åœ‹è€ƒå¤±æ•—] --> B{æ˜¯å¦å …æŒå¾é†«?}
    B -->|æ˜¯| C[è€ƒAMC]
    C -->|åŠæ ¼| D[ç•¶æ¾³æ´²intern]
    C -->|ä¸åŠæ ¼| E[å»ç¾åœ‹å¯¦ç¿’]
    B -->|å¦| F[è½‰æ›é ˜åŸŸ: é†«ç™‚ç›¸é—œ/éé†«ç™‚]
    F -->|é†«ç™‚ç›¸é—œ| G[é†«å­¸é¡§å•/PA/NP]
    F -->|éé†«ç™‚| H[ç§‘æŠ€æ¥­/å‰µæ¥­]
    E --> I{æ˜¯å¦ç²å¾—äººè„ˆæˆ–æ¨è–¦ä¿¡?}
    I --> |æ˜¯| J[è€ƒUSMLE]
    I --> |å¦| K[é‡è€ƒè‡ºç£é†«å¸«åœ‹è€ƒ115-1]
```

<script src='https://unpkg.com/mermaid@8.1.0/dist/mermaid.min.js'></script>

<div class='mermaid'>
graph TD;
A[å·²ç•¢æ¥­ä½†åœ‹è€ƒå¤±æ•—] --> B{æ˜¯å¦å …æŒå¾é†«?}
B -->|æ˜¯| C[è€ƒAMC]
C -->|åŠæ ¼| D[ç•¶æ¾³æ´²intern]
C -->|ä¸åŠæ ¼| E[å»ç¾åœ‹å¯¦ç¿’]
B -->|å¦| F[è½‰æ›é ˜åŸŸ: é†«ç™‚ç›¸é—œ/éé†«ç™‚]
F -->|é†«ç™‚ç›¸é—œ| G[é†«å­¸é¡§å•/PA/NP]
F -->|éé†«ç™‚| H[ç§‘æŠ€æ¥­/å‰µæ¥­]
E --> I{æ˜¯å¦ç²å¾—äººè„ˆæˆ–æ¨è–¦ä¿¡?}
I --> |æ˜¯| J[è€ƒUSMLE]
I --> |å¦| K[é‡è€ƒè‡ºç£é†«å¸«åœ‹è€ƒ115-1]
</div>

è‡ºç£å¤±æ•—ç‚ºä½•å„ªå…ˆè€ƒæ…®æ¾³æ´²ï¼Ÿ > åœ‹è€ƒæ¯”è‡ºç£å¥½è€ƒï¼Œé€šéå¾Œåœ¨åé„‰å¹¾ä¹ä¿è­‰å°±æ¥­ã€‚

æ¾³æ´²å¤±æ•—ç‚ºä½•å„ªå…ˆè€ƒæ…®ç¾åœ‹ï¼Ÿ > åœ‹è€ƒåªéœ€å¼„ç†Ÿç‰¹å®šçš„ä¸»é¡Œï¼ˆä½†éœ€ç†è§£æ©Ÿè½‰ï¼Œæ˜¯å¦æ¯”è‡ºç£å¥½è€ƒçœ‹äººï¼‰ï¼Œç«¶çˆ­å¹¾ä¹åªæ†‘é‹æ°£ä¸æ†‘å¯¦åŠ›ã€‚

ç¾åœ‹å¤±æ•—ç‚ºä½•å„ªå…ˆè€ƒæ…®é‡è€ƒï¼Ÿ > åŒå€‹è€ƒè©¦è€ƒç¬¬2æ¬¡é€šå¸¸æˆç¸¾æ¯”ç¬¬1æ¬¡å¥½ï¼Œé€šéå¾Œåœ¨å°åŒ—ä»¥å¤–å¹¾ä¹ä¿è­‰å°±æ¥­ã€‚

---  

å»ºè­°å„ªå…ˆè©•ä¼°ã€Œæ™‚é–“æˆæœ¬ã€èˆ‡ã€Œåœ°ç†å½ˆæ€§ã€ï¼Œå¿…è¦æ™‚å¯è¯ç¹«å°ˆæ¥­ç§»æ°‘å¾‹å¸«ï¼ˆå¦‚MAG Immigrationï¼‰ã€‚






### **å®¹æ˜“è¢«å¿½ç•¥çš„ã€Œå¿«é€Ÿé€šé“ã€**
1. **æ„›çˆ¾è˜­**ï¼š  
   - æ­ç›Ÿç•¢æ¥­ç”Ÿå¯ç›´æ¥è¨»å†Š  
   - éæ­ç›Ÿç”Ÿéœ€å®Œæˆã€Œè‡¨åºŠé©æ‡‰æœŸã€ï¼ˆ6-12å€‹æœˆï¼‰  

2. **é¦¬ä¾†è¥¿äº**ï¼š  
   - æ‰¿èªéƒ¨åˆ†è‹±åœ‹/æ¾³æ´²å­¸æ ¡å­¸æ­·  
   - ç­†è©¦å¾Œåƒ…éœ€é¢è©¦ï¼ˆç„¡è‡¨åºŠè€ƒï¼‰  

3. **è‘¡è„ç‰™**ï¼š  
   - æ­ç›Ÿå­¸æ­·+è‘¡èªB2å¯å…è©¦è¨»å†Š  
   - éæ­ç›Ÿç”Ÿéœ€åƒåŠ PROVA COMUMï¼ˆé€šéç‡65%ï¼‰  

### **å„åœ‹ã€Œæ¨è–¦ä¿¡ã€é‡è¦æ€§æ¯”è¼ƒ**
- **æ¥µé«˜æ¬Šé‡**ï¼š  
  - ç¾åœ‹ï¼ˆéœ€3-4å°LORï¼Œå«Chair Letterï¼‰  
  - åŠ æ‹¿å¤§ï¼ˆCaRMSéœ€è©³ç´°è©•ä¼°è¡¨ï¼‰  

- **ä¸­ç­‰æ¬Šé‡**ï¼š  
  - è‹±åœ‹ï¼ˆè‡³å°‘1å°ä¾†è‡ªè‹±åœ‹é†«å¸«ï¼‰  
  - æ¾³æ´²ï¼ˆéœ€2å°ï¼Œå…¶ä¸­1å°éœ€æœ¬åœ°é†«å¸«ï¼‰  

- **å¹¾ä¹ä¸éœ€**ï¼š  
  - ä¸­åœ‹ã€æ—¥æœ¬ï¼ˆä»¥è€ƒè©¦æˆç¸¾ç‚ºä¸»ï¼‰  
  - å¾·åœ‹ï¼ˆå–æ±ºæ–¼å£è©¦è¡¨ç¾ï¼‰  

### **é¸æ“‡ç­–ç•¥å»ºè­°**
1. **èªè¨€èƒ½åŠ›å„ªå…ˆ**ï¼š  
   - è‹±èªä½³ â†’ ç„æº–è‹±æ¾³åŠ   
   - æŒæ¡ç¬¬äºŒå¤–èª â†’ è€ƒæ…®å¾·æ—¥æ³•  

2. **ç¶“æ¿Ÿæˆæœ¬è€ƒé‡**ï¼š  
   - é ç®—æœ‰é™ â†’ é¦¬ä¾†è¥¿äºï¼ˆè€ƒè©¦è²»ç´„$500ç¾å…ƒï¼‰  
   - é¡˜æŠ•è³‡ â†’ ç¾åœ‹ï¼ˆUSMLE+Matchç¸½èŠ±è²»ç´„$1.5è¬ç¾å…ƒï¼‰  

3. **æ™‚é–“æ•ˆç‡**ï¼š  
   - æœ€å¿«å–è­‰ï¼šè‘¡è„ç‰™ï¼ˆ6å€‹æœˆèªè¨€+è¨»å†Šï¼‰  
   - æœ€æ…¢é€”å¾‘ï¼šåŠ æ‹¿å¤§ï¼ˆå¹³å‡éœ€3å¹´åŒ¹é…ä½é™¢é†«å¸«ï¼‰  

### **é¢¨éšªæé†’**
- **è‹±åœ‹**ï¼š2024å¹´èµ·UKMLAå°‡å¢åŠ æƒ…å¢ƒåˆ¤æ–·é¡Œï¼ˆSJTï¼‰æ¯”é‡  
- **æ¾³æ´²**ï¼š2025å¹´å¯èƒ½æé«˜é›…æ€è¦æ±‚è‡³4å€‹7  
- **å¾·åœ‹**ï¼š2023å¹´æ–°è¦è¦æ±‚éæ­ç›Ÿç”Ÿéœ€å…ˆé€šéã€Œå°ˆæ¥­èªè¨€è€ƒè©¦ã€  

å»ºè­°è¡Œå‹•æ­¥é©Ÿï¼š  
1. å…ˆç¢ºèªç›®æ¨™åœ‹å®¶çš„ã€Šå¤–åœ‹é†«å­¸ç”Ÿæœ€æ–°è¨»å†ŠæŒ‡å—ã€‹  
2. è¯ç¹«è©²åœ‹é†«å­¸ç”Ÿå”æœƒï¼ˆå¦‚å¾·åœ‹çš„Marburger Bundï¼‰  
3. åƒåŠ ç›®æ¨™åœ‹å®¶çš„è€ƒå‰å·¥ä½œåŠï¼ˆå¦‚AMC OSCEæ¨¡æ“¬è€ƒï¼‰  

### **ç¾åœ‹å¯¦ç¿’ä»£è¾¦å…¬å¸**
[AMO](https://www.amopportunities.org/)

[USMLE Sarthi](https://www.usmlesarthi.com/)

[Rotation Plus](https://rotationsplus.com/)

[VSLO](https://students-residents.aamc.org/visiting-student-learning-opportunities/visiting-student-learning-opportunities-contact-form) (å·²ç•¢æ¥­ç„¡æ³•ç”¨)

[Clinician Nexus](https://cliniciannexus.com/) (å…è²»)

å¼·åŠ›æ¨è–¦ä¿¡5å¤§è¦ä»¶:
1. **ä¾†è‡ªå¥½çš„programã€‚** ç¾åœ‹å¯¦ç¿’ç¶“é©—ç”±å„ªåˆ°åŠ£æ’åº: University-affiliated clinical (å·²ç•¢æ¥­ç„¡æ³•ç”¨) > Inpatient clinical > Outpatient clinical > Observership > Research > Virtual
2. **Waived letterã€‚** ç”±å¯¦ç¿’æ©Ÿæ§‹ä¸Šå‚³ï¼Œå‹¿è‡ªå·±ä¸Šå‚³ã€‚
3. **ç¬¦åˆæ ¼å¼ã€‚** ç”±è€å¸«å¯«ï¼Œå‹¿è‡ªå·±å¯«ã€‚è‹¥è€å¸«è«‹ä½ è‡ªå·±æ‰“è‰ç¨¿ï¼Œç›´æ¥æ”¹æ‰¾å…¶ä»–è€å¸«ã€‚
4. **æ™‚æ•ˆæ€§ã€‚** è«‹è€å¸«ç­‰ä½ çš„ Match Cycle é–‹å§‹å¾Œå†å¯«ï¼ˆæŠ¼æ—¥æœŸï¼‰
5. **éš¨ä¿¡è‡´é›»ã€‚** è«‹è€å¸«æ‰“é›»è©±çµ¦ä½ è¦ç”³è«‹çš„é†«é™¢ã€‚

### **è€ƒè©¦æº–å‚™è³‡æº**
#### **ç¾åœ‹ (USMLE)**
  
  - **UWorld**ï¼ˆå¿…å‚™ï¼‰ï¼šé«˜è³ªé‡é¡Œåº«ï¼Œè©³è§£æ¸…æ™°ï¼Œé©åˆStep 1ï¼ˆç¾ç‚ºP/Fï¼‰ã€Step 2 CKã€‚  
  - **First Aid**ï¼šæ¿ƒç¸®é‡é»ï¼Œæ­é…UWorldä½¿ç”¨ã€‚  
  - **NBME**ï¼šå®˜æ–¹æ¨¡æ“¬é¡Œï¼Œé æ¸¬åˆ†æ•¸æº–ç¢ºã€‚  

#### **è‹±åœ‹ (PLAB/UKMLA)**
  
  - **Pastest**ï¼šé¡ä¼¼UWorldï¼Œæä¾›PLAB 1å’Œ2çš„é¡Œåº«èˆ‡æ¨¡æ“¬è€ƒã€‚  
  - **BMJ OnExamination**ï¼šå®˜æ–¹åˆä½œé¡Œåº«ï¼Œè²¼è¿‘å¯¦éš›è€ƒè©¦é¢¨æ ¼ã€‚  
  - **PLABABLE**ï¼šå…è²»é¡Œåº«+è©³è§£ï¼Œé©åˆé ç®—æœ‰é™çš„è€ƒç”Ÿã€‚  

#### **åŠ æ‹¿å¤§ (MCCQE)**
  
  - **CanadaQBank**ï¼šå°ˆç‚ºMCCQE Part 1è¨­è¨ˆï¼Œé¡Œç›®æ¶µè“‹åŠ æ‹¿å¤§è‡¨åºŠæŒ‡å—ã€‚  
  - **UWorld**ï¼ˆéƒ¨åˆ†é©ç”¨ï¼‰ï¼šStep 2 CKå…§å®¹èˆ‡MCCQEéƒ¨åˆ†é‡ç–Šï¼Œä½†éœ€è£œå……åŠ æ‹¿å¤§ç‰¹å®šæŒ‡å—ï¼ˆå¦‚CPGï¼‰ã€‚  
  - **Toronto Notes**ï¼šåŠ æ‹¿å¤§ç‰ˆã€ŒFirst Aidã€ï¼Œæ•´åˆè‡¨åºŠçŸ¥è­˜èˆ‡è€ƒè©¦é‡é»ã€‚  

#### **æ¾³æ´² (AMC)**
  
  - **AMC QBank**ï¼šå®˜æ–¹åˆä½œé¡Œåº«ï¼Œæ¶µè“‹ç­†è©¦å’Œè‡¨åºŠè€ƒè©¦ï¼ˆOSCEï¼‰ã€‚  
  - **Rapid Review Series**ï¼ˆæ¾³æ´²ç‰ˆï¼‰ï¼šé¡ä¼¼First Aidï¼Œé‡å°AMCè€ƒè©¦è¨­è¨ˆã€‚  
  - **Practice OSCE Stations**ï¼šAMCè‡¨åºŠè€ƒéœ€å¤§é‡æ¨¡æ“¬ç·´ç¿’ã€‚
  - **Amedex**
  - **AceAmcQ**

#### **å¾·åœ‹ (FSP/Approbation)**
 
  - **Amboss**ï¼ˆå¾·èªç‰ˆï¼‰ï¼šå¾·åœ‹é†«å­¸ç”Ÿçš„ã€ŒUWorldã€ï¼Œå«é¡Œåº«å’Œè‡¨åºŠçŸ¥è­˜åº«ã€‚  
  - **Thieme Examensfragen**ï¼šæ­·å±†åœ‹è€ƒé¡Œåº«ï¼Œé©åˆFSPç­†è©¦ã€‚  
  - **Mediscript KurzlehrbÃ¼cher**ï¼šæ¿ƒç¸®é‡é»ï¼Œé©åˆå£è©¦æº–å‚™ã€‚  

#### **æ—¥æœ¬ (é†«å¸«åœ‹å®¶è©¦é©—)**
  
  - **QBã‚ªãƒ³ãƒ©ã‚¤ãƒ³**ï¼šæ—¥æœ¬ç‰ˆUWorldï¼Œé¡Œåº«é¾å¤§ä¸”æ›´æ–°å¿«ã€‚  
  - **ç—…æ°—ãŒã¿ãˆã‚‹**ï¼ˆç³»åˆ—æ›¸ç±ï¼‰ï¼šåœ–æ–‡ä¸¦èŒ‚çš„è‡¨åºŠé‡é»æ•´ç†ã€‚  
  - **éå»å•å…¨é›†**ï¼šæ­·å±†è€ƒé¡Œæ˜¯å‚™è€ƒæ ¸å¿ƒã€‚  

#### **ä¸­åœ‹ (é†«å¸«è³‡æ ¼è€ƒè©¦)**
 
  - **é†«å­¸æ•™è‚²ç¶²é¡Œåº«**ï¼šè¦†è“‹90%ä»¥ä¸Šè€ƒé»ï¼Œå«å¤§é‡è¨˜æ†¶å‹é¡Œç›®ã€‚  
  - **è³€éŠ€æˆç³»åˆ—**ï¼šä¸­åœ‹ç‰ˆFirst Aidï¼Œç­†è©¦è¡åˆºå¿…å‚™ã€‚  
  - **æ­·å¹´çœŸé¡Œ**ï¼šè€ƒè©¦é‡è¤‡ç‡é«˜ï¼Œéœ€åè¦†ç·´ç¿’ã€‚  

---

### **åœ‹éš›é€šç”¨è³‡æº**
- **Amboss**ï¼š  
  - é©ç”¨å¤šåœ‹è€ƒè©¦ï¼ˆå¾·ã€ç¾ã€è‹±ï¼‰ï¼ŒçŸ¥è­˜åº«å¼·å¤§ï¼Œä½†éœ€ä¾ç›®æ¨™åœ‹å®¶ç¯©é¸å…§å®¹ã€‚  
- **Anki**ï¼š  
  - è‡ªè£½è¨˜æ†¶å¡ï¼ˆå¦‚ã€ŒDope Medical Scienceã€ç‰Œçµ„ï¼‰é©åˆå„åœ‹è€ƒè©¦çš„åŸºç¤çŸ¥è­˜éå›ºã€‚  
- **PubMed/UpToDate**ï¼š  
  - è§£æ±ºè‡¨åºŠé›£é¡Œï¼Œä½†éœ€æ­é…é¡Œåº«ä½¿ç”¨ã€‚  

---

### **é¸æ“‡ç­–ç•¥**
1. **å„ªå…ˆä½¿ç”¨ã€Œæœ¬åœŸåŒ–ã€é¡Œåº«**ï¼š  
   - ä¾‹å¦‚è€ƒPLABç”¨Pastestï¼Œè€ƒAMCç”¨AMC QBankã€‚  
2. **è¼”ä»¥åœ‹éš›è³‡æº**ï¼š  
   - è‹¥ç›®æ¨™åœ‹å®¶è³‡æºä¸è¶³ï¼ˆå¦‚éæ´²åœ‹å®¶ï¼‰ï¼Œå¯ç”¨UWorldæˆ–Ambossè£œå¼·ã€‚  
3. **å–„ç”¨å®˜æ–¹æ¨¡æ“¬é¡Œ**ï¼š  
   - å¦‚MCCQEçš„NAC OSCEæ¨¡è€ƒã€æ—¥æœ¬çš„ã€Œæ¨¡æ“¬è©¦é¨“ã€ã€‚  

---

### **æ³¨æ„äº‹é …**
- **èªè¨€éšœç¤™**ï¼šéè‹±èªè€ƒè©¦ï¼ˆå¦‚å¾·ã€æ—¥ï¼‰éœ€å„ªå…ˆæŒæ¡å°ˆæ¥­è¡“èªã€‚  
- **è€ƒè©¦å½¢å¼å·®ç•°**ï¼š  
  - ç¾åœ‹USMLEé‡è‡¨åºŠæ¨ç†ï¼Œä¸­åœ‹è€ƒè©¦é‡è¨˜æ†¶ï¼Œè‹±åœ‹PLABé‡æƒ…å¢ƒåˆ¤æ–·ã€‚  
- **æ›´æ–°é »ç‡**ï¼š  
  - UWorldæ¯å¹´æ›´æ–°ï¼Œè€Œéƒ¨åˆ†åœ‹å®¶é¡Œåº«ï¼ˆå¦‚ä¸­åœ‹ï¼‰å¯èƒ½å«éæ™‚å…§å®¹ï¼Œéœ€äº¤å‰é©—è­‰ã€‚  



 

---

## **ç¶œåˆæ¯”è¼ƒè¡¨**

| åœ‹å®¶   | åœ‹è€ƒé›£åº¦-æ·±åº¦ï¼ˆ0-5â˜…ï¼‰ | åœ‹è€ƒé›£åº¦-å»£åº¦ï¼ˆ0-5â˜…ï¼‰ | åœ‹è€ƒé—œéµæŒ‘æˆ°                     | åŠæ ¼ç‡ | ä½é™¢é†«å¸«éŒ„å–é‹æ°£æˆåˆ† | éŒ„å–é—œéµå› ç´  |
|--------|-------------|-------------|-----------------------------|--------|----------------------|--------------|
| **ç¾åœ‹** | â˜…â˜…â˜…â˜…â˜†       | â˜…â˜…â˜…â˜†â˜†       | è‡¨åºŠæ•´åˆ + æœ€æ–°æ–‡ç»æ‡‰ç”¨       | 90-95% | **æ¥µé«˜** | Step 2 CKã€æ¨è–¦ä¿¡ |
| **å¾·åœ‹** | â˜…â˜…â˜…â˜…â˜…       | â˜…â˜…â˜†â˜†â˜†       | åŸºç¤ç§‘å­¸ + å¾·èªç²¾æº–åº¦         | 70-80% | **ä½**ï¼ˆç¼ºé†«å¸«ï¼‰ | å¾·èªèƒ½åŠ›ã€åœ‹è€ƒæˆç¸¾ |
| **æ¾³æ´²** | â˜…â˜…â˜…â˜†â˜†       | â˜…â˜…â˜…â˜†â˜†       | æœ¬åœŸæŒ‡å— + æ–‡åŒ–èƒ½åŠ›           | 20-30% | ä¸­é«˜ | å·åˆ¥é…é¡ã€è‡¨åºŠç¶“é©— |
| **è‹±åœ‹** | â˜…â˜…â˜…â˜†â˜†       | â˜…â˜…â˜…â˜…â˜†       | NHS æµç¨‹ + è‡¨åºŠåˆ¤æ–·           | 70-80% | é«˜ | PLAB æˆç¸¾ã€è‡¨åºŠç¶“é©— |
| **å°ç£** | â˜…â˜…â˜…â˜…â˜†       | â˜…â˜…â˜…â˜…â˜…       | é¡Œé‡é¾å¤§ + è¨˜æ†¶å‹å…§å®¹         | 70-90% | ä¸­ï¼ˆç†±é–€ç§‘åˆ¥ç«¶çˆ­å¤§ï¼‰ | PGY è¡¨ç¾ã€é¢è©¦ |
| **ä¸­åœ‹** | â˜…â˜…â˜†â˜†â˜†       | â˜…â˜…â˜…â˜…â˜…       | æ³•è¦ + ä¸­é†«è¥¿é†«æ··åˆ           | 50-60% | **æ¥µé«˜**ï¼ˆé é—œä¿‚ï¼‰ | è€ƒè©¦æˆç¸¾ã€äººè„ˆ |
| **æ—¥æœ¬** | â˜…â˜…â˜…â˜†â˜† | â˜…â˜…â˜…â˜…â˜… | æ—¥æœ¬ç‰¹æœ‰çš„é†«ç™‚æŒ‡å— | 90%         | ä¸­ï¼ˆç†±é–€é†«é™¢ç«¶çˆ­å¤§ï¼‰ | åœ‹è€ƒæˆç¸¾ã€é¢è©¦ |

* é‹æ°£æˆåˆ†: å–æ±ºæ–¼åˆ°è©²åœ‹å¯¦ç¿’æ™‚è€å¸«å°ä½ çš„å°è±¡ã€è€å¸«æ˜¯å¦é¡˜æ„å¹«ä½ ã€è€å¸«çš„äººè„ˆã€è€å¸«çš„èƒ½åŠ›
* ç¾åœ‹åŠæ ¼ç‡æœ€é«˜ä¸ä»£è¡¨æœ€ç°¡å–®ã€‚ç¾åœ‹é†«å­¸é™¢USMLEé€šéç‡æ˜¯æ•™å­¸è©•é‘‘KPIï¼Œå› æ­¤å­¸æ ¡å¤šå……ç•¶åœ‹è€ƒè¤‡ç¿’ç­ï¼Œä¸”é†«é™¢è¦æ±‚é«˜æˆç¸¾ï¼Œè¨­æ¯”é€šéæ›´é«˜çš„åˆ†æ•¸é–€æª»ï¼ˆé–€æª»å¯è‡³é†«é™¢æ•™å­¸éƒ¨æŸ¥è©¢ä½é™¢é†«å¸«ç”³è«‹æ¢ä»¶ï¼‰ï¼Œæ‰€ä»¥USMLEè€ƒç”Ÿå¤šå……åˆ†æº–å‚™ã€‚
* æ¾³æ´²åŠæ ¼ç‡æœ€ä½ä¸ä»£è¡¨æœ€é›£ã€‚æ¾³æ´²é†«å­¸é™¢ç•¢æ¥­ç”Ÿä¸ç”¨è€ƒAMCï¼ŒAMCè€ƒç”Ÿå…¨æ˜¯IMGï¼Œå¤šä¸éœ€è¦å»æ¾³æ´²ï¼Œåªæ˜¯è€ƒè€ƒçœ‹ï¼Œæ²’å……åˆ†æº–å‚™ã€‚

### **æå‡ä½é™¢é†«å¸«éŒ„å–é‹æ°£çš„å‹™å¯¦ç­–ç•¥**  

#### **1. å»ºç«‹é—œéµäººè„ˆï¼Œä½†é¿å…ç„¡å„Ÿå‹å‹•**  
- **ç­–ç•¥**ï¼š  
  - **ä¸»å‹•å”åŠ©** ä¸»æ²»é†«å¸«ï¼ˆå¦‚æ•´ç†æ–‡ç»ã€å”åŠ©è‡¨åºŠäº‹å‹™ï¼‰ï¼Œä½† **æ˜ç¢ºè¡¨é”ç›®æ¨™**ï¼ˆä¾‹å¦‚ï¼šã€Œè€å¸«ï¼Œæˆ‘å¾ˆæƒ³ç”³è«‹XXç§‘ï¼Œèƒ½å¦è«‹æ‚¨æ¨è–¦ï¼Ÿã€ï¼‰ã€‚  
  - **ä¸æ¥å—ã€Œç¹è·¯ã€æ¢ä»¶**ï¼ˆå¦‚ç´”ç ”ç©¶è·ç¼ºï¼‰ï¼Œé™¤éè©²è·ä½èƒ½ **ç›´æ¥é€£çµä½é™¢é†«å¸«ç¼ºé¡**ã€‚  
- **æ³¨æ„**ï¼š  
  - è¯äººå‹¤å‹å½¢è±¡å¯åŠ åˆ†ï¼Œä½†éœ€é¿å…è¢«ç•¶æˆã€Œå…è²»å‹å·¥ã€ã€‚  

#### **2. åˆ†æ•£é¢¨éšªï¼šå»£çµå–„ç·£**  
- **æ–¹æ³•**ï¼š  
  - åŒæ™‚èˆ‡ **3-5ä½ä¸»æ²»é†«å¸«** ä¿æŒè‰¯å¥½äº’å‹•ï¼Œå¢åŠ æ¨è–¦æ©Ÿæœƒã€‚  
  - **ä¸æŠ¼æ³¨å–®ä¸€å°å¸«**ï¼ˆé¿å…æ™‚é–“æµªè²»åœ¨ç„¡æ•ˆé—œä¿‚ä¸Šï¼‰ã€‚  
- **é—œéµå•é¡Œ**ï¼š  
  - ã€Œè€å¸«ï¼Œæ‚¨è¦ºå¾—æˆ‘çš„èƒŒæ™¯é©åˆç”³è«‹å“ªäº›é†«é™¢ï¼Ÿèƒ½å¦å¼•è–¦ï¼Ÿã€  

#### **3. ä¿æŒæ•éŠ³ï¼ŒæŒæ¡éš±è—æ©Ÿæœƒ**  
- **è¡Œå‹•**ï¼š  
  - å®šæœŸåƒåŠ  **é†«é™¢æ™¨æœƒã€ç—…ä¾‹è¨è«–**ï¼Œéœ²è‡‰å¢åŠ å°è±¡åˆ†ã€‚  
  - èˆ‡ä½é™¢é†«å¸«ã€è¡Œæ”¿äººå“¡äº¤æµï¼Œæ‰“è½ **æœªå…¬é–‹ç¼ºé¡**ï¼ˆå¦‚æœ‰äººè‡¨æ™‚é›¢è·ï¼‰ã€‚  
- **å¿ƒæ…‹**ï¼š  
  - æ¨‚è§€ä½†ç¾å¯¦ï¼Œæ¥å—ã€Œé‹æ°£æ˜¯ç•™çµ¦æº–å‚™å¥½çš„äººã€ã€‚  

#### **4. å…·é«”äº¤æ›æ¢ä»¶ç¯„ä¾‹**  
- **æˆåŠŸæ¡ˆä¾‹**ï¼š  
  - ã€Œè€å¸«ï¼Œæˆ‘å¹«æ‚¨å®Œæˆé€™ç¯‡è«–æ–‡ï¼Œèƒ½å¦è«‹æ‚¨æ‰“é›»è©±çµ¦XXé†«é™¢PDï¼ˆProgram Directorï¼‰ï¼Ÿã€  
  - ã€Œæˆ‘é›™å‘å›é¥‹çµ¦ä½ æ»¿åˆ†ä¸¦æ¨è–¦æ›´å¤šå°ç£äººä¾†æ‚¨é€™å¯¦ç¿’ï¼Œçµè¨“æ™‚èƒ½å¦å¯«ä¸€å°å¼·åŠ›æ¨è–¦ä¿¡ï¼Ÿã€  

#### **5. é¿å…åœ°é›·**  
- **ä¸ç•¶è¡Œç‚º**ï¼š  
  - åªåšäº‹ä¸é–‹å£ï¼ˆæ²’äººçŸ¥é“ä½ æƒ³è¦ä»€éº¼ï¼‰ã€‚  
  - ç³¾çµæ–¼ã€Œå…¬å¹³æ€§ã€ï¼ˆè³‡æºæœ¬ä¾†å°±ä¸å¹³ç­‰ï¼Œé‡é»æ˜¯å–å¾—å…¥å ´åˆ¸ï¼‰ã€‚  

---

### **ç¸½çµï¼šä¸»å‹•å‰µé€ ã€Œå¯æ§çš„é‹æ°£ã€**  
1. **ç›®æ¨™å°å‘**ï¼šæ¯ä»½ä»˜å‡ºéƒ½æ‡‰é€£çµåˆ°ã€Œæ¨è–¦ä¿¡/é¢è©¦æ©Ÿæœƒã€ã€‚  
2. **å¤šå…ƒä½ˆå±€**ï¼šåˆ†æ•£æŠ•è³‡å¤šä½å°å¸«ï¼Œé™ä½é¢¨éšªã€‚  
3. **æƒ…å ±å„ªå…ˆ**ï¼šæŒæ¡å…§éƒ¨æ¶ˆæ¯æ¯”ç›²ç›®åŠªåŠ›æ›´é‡è¦ã€‚  



---
ä»¥ä¸‹æ˜¯å„å›½åœ¨å½•å–ä½é™¢åŒ»å¸ˆæ—¶çš„æ ¸å¿ƒä¾§é‡ç‚¹åˆ†æï¼Œç»“åˆåŒ»å­¦æ•™è‚²ä¸åŒ»ç–—ä½“ç³»çš„ç‰¹ç‚¹ï¼š

---

### **1. ç¾å›½ï¼šé‡è§†ã€Œå®ŒæˆåŸ¹è®­çš„èƒ½åŠ›ã€**  
- **æ ¸å¿ƒè¦æ±‚**ï¼š  
  - é€šè¿‡ **USMLEè€ƒè¯•**ï¼ˆStep 1ã€Step 2 CK/CSã€Step 3ï¼‰è¯æ˜å­¦æœ¯ä¸ä¸´åºŠèƒ½åŠ›ã€‚  
  - **ä½é™¢åŒ»å¸ˆåŒ¹é…ï¼ˆMatchï¼‰** ä¸­ï¼Œå¼ºè°ƒç”³è¯·è€…çš„ **é•¿æœŸå­¦ä¹ æ½œåŠ›** å’Œ **é€‚åº”é«˜å¼ºåº¦åŸ¹è®­** çš„èƒ½åŠ›ï¼Œå¦‚æ¨èä¿¡ã€ç ”ç©¶ç»å†ã€ä¸ªäººé™ˆè¿°ä¸­ä½“ç°çš„åšæŒåŠ›ã€‚  
- **åŸå› **ï¼š  
  - ç¾å›½ä½é™¢åŒ»å¸ˆåŸ¹è®­æ·˜æ±°ç‡é«˜ï¼Œéœ€ç¡®ä¿å€™é€‰äººæœ‰è¶³å¤Ÿçš„æŠ—å‹èƒ½åŠ›å’Œå®Œæˆå…¨ç¨‹åŸ¹è®­çš„ç¨³å®šæ€§ã€‚  

---

### **2. æ¾³å¤§åˆ©äºšï¼šé‡è§†ã€Œå³æˆ˜èƒ½åŠ›ã€**  
- **æ ¸å¿ƒè¦æ±‚**ï¼š  
  - é€šè¿‡ **AMCè€ƒè¯•** å’Œ **12ä¸ªæœˆå®ä¹ **ï¼Œç¡®ä¿ä¸´åºŠæŠ€èƒ½å¯ç›´æ¥åº”ç”¨äºåŸºå±‚åŒ»ç–—ã€‚  
  - å…¨ç§‘åŒ»ç”ŸåŸ¹è®­å¼ºè°ƒ **ç»¼åˆè¯Šç–—èƒ½åŠ›**ï¼Œå¦‚æ…¢æ€§ç—…ç®¡ç†ã€æ€¥è¯Šå¤„ç†ã€ç¤¾åŒºå¥åº·æœåŠ¡ç­‰ï¼Œä»¥å¿«é€Ÿé€‚åº”åè¿œåœ°åŒºæˆ–å¤šå…ƒæ–‡åŒ–ç¯å¢ƒã€‚  
- **åŸå› **ï¼š  
  - æ¾³å¤§åˆ©äºšåŒ»ç–—ä½“ç³»ä¾èµ–å…¨ç§‘åŒ»ç”Ÿä½œä¸ºåˆçº§åŒ»ç–—æ ¸å¿ƒï¼Œéœ€å‡å°‘å¯¹åŒ»é™¢ç³»ç»Ÿçš„è´Ÿæ‹…ï¼Œå› æ­¤é‡è§†æ¯•ä¸šç”Ÿçš„ç‹¬ç«‹æ‰§ä¸šèƒ½åŠ›ã€‚  

---

### **3. è‹±å›½ï¼šé‡è§†ã€Œä¸´åºŠç»éªŒä¸ NHS ä½“ç³»é€‚åº”åŠ›ã€**  
- **æ ¸å¿ƒè¦æ±‚**ï¼š  
  - é€šè¿‡ **PLABè€ƒè¯•** åï¼Œéœ€å®Œæˆ **FY1/FY2** åŸºç¡€åŸ¹è®­ï¼Œç†Ÿæ‚‰ NHSï¼ˆå›½å®¶åŒ»ç–—æœåŠ¡ä½“ç³»ï¼‰æµç¨‹ã€‚  
  - éæ¬§ç›ŸåŒ»å­¦ç”Ÿéœ€è¯æ˜ **è‹±è¯­æ²Ÿé€šèƒ½åŠ›**ï¼ˆå¦‚é›…æ€/OETï¼‰å’Œ **è·¨æ–‡åŒ–åŒ»ç–—ç»éªŒ**ã€‚  
- **åŸå› **ï¼š  
  - NHS ä½“ç³»å¼ºè°ƒæ ‡å‡†åŒ–è¯Šç–—å’Œå›¢é˜Ÿåä½œï¼Œå€™é€‰äººéœ€å¿«é€Ÿèå…¥ä»¥æ‚£è€…ä¸ºä¸­å¿ƒçš„åŒ»ç–—æ¨¡å¼ã€‚  

---

### **4. å¾·å›½ï¼šé‡è§†ã€Œä¸“ä¸šçŸ¥è¯†æ·±åº¦ä¸è¯­è¨€èƒ½åŠ›ã€**  
- **æ ¸å¿ƒè¦æ±‚**ï¼š  
  - é€šè¿‡ **Staatsexamen** å›½å®¶è€ƒè¯•ï¼ˆå«ç¬”è¯•ä¸å£è¯•ï¼‰ï¼Œè€ƒæ ¸åŸºç¡€åŒ»å­¦ä¸ä¸´åºŠæ•´åˆèƒ½åŠ›ã€‚  
  - **å¾·è¯­C1æ°´å¹³** æ˜¯æ³¨å†Œå‰æï¼Œç¡®ä¿ä¸æ‚£è€…æ— éšœç¢æ²Ÿé€šã€‚  
- **åŸå› **ï¼š  
  - å¾·å›½åŒ»ç–—ä½“ç³»é«˜åº¦ä¸“ä¸šåŒ–ï¼Œä¸”åŒ»æ‚£æ²Ÿé€šä¾èµ–ç²¾å‡†æœ¯è¯­ï¼Œè¯­è¨€ä¸å­¦æœ¯èƒ½åŠ›ç¼ºä¸€ä¸å¯ã€‚  

---

### **5. æ—¥æœ¬ï¼šé‡è§†ã€Œä¸´åºŠå®è·µä¸æœ¬åœŸåˆ¶åº¦é€‚åº”ã€**  
- **æ ¸å¿ƒè¦æ±‚**ï¼š  
  - é€šè¿‡ **åŒ»å¸ˆå›½å®¶è¯•éªŒ** åï¼Œéœ€å®Œæˆ **2å¹´åˆæ¬¡ç ”ä¿®**ï¼ˆç±»ä¼¼ä½é™¢åŒ»å¸ˆåŸ¹è®­ï¼‰ï¼ŒæŒæ¡æ—¥æœ¬ç‰¹æœ‰çš„åŒ»ç–—æµç¨‹ã€‚  
  - é‡è§† **å›¢é˜Ÿåä½œ** å’Œ **é•¿æœŸèŒä¸šç¨³å®šæ€§**ï¼ˆå¦‚é€‰æ‹©ç•™åœ¨åœ°æ–¹åŒ»é™¢ï¼‰ã€‚  
- **åŸå› **ï¼š  
  - æ—¥æœ¬åŒ»ç–—ä½“ç³»æ³¨é‡ç²¾ç»†åŒ–ç®¡ç†å’Œæ‚£è€…é•¿æœŸç…§æŠ¤ï¼Œéœ€åŒ»ç”Ÿé€‚åº”é«˜å¼ºåº¦ã€é«˜çºªå¾‹çš„å·¥ä½œç¯å¢ƒã€‚  

---

### **6. åŠ æ‹¿å¤§ï¼šé‡è§†ã€Œç¤¾åŒºæœåŠ¡ä¸å¤šå…ƒæ–‡åŒ–æ•æ„Ÿåº¦ã€**  
- **æ ¸å¿ƒè¦æ±‚**ï¼š  
  - ç”³è¯·ä½é™¢åŒ»å¸ˆæ—¶éœ€å±•ç¤º **ç¤¾åŒºæœåŠ¡ç»éªŒ**ï¼ˆå¦‚åè¿œåœ°åŒºåŒ»ç–—æ”¯æ´ï¼‰ã€‚  
  - é€šè¿‡ **NAC OSCE** è€ƒæ ¸ä¸´åºŠæŠ€èƒ½æ—¶ï¼Œæ³¨é‡å¯¹å¤šå…ƒæ–‡åŒ–æ‚£è€…çš„æ²Ÿé€šèƒ½åŠ›ã€‚  
- **åŸå› **ï¼š  
  - åŠ æ‹¿å¤§åŒ»ç–—èµ„æºåˆ†å¸ƒä¸å‡ï¼Œä¸”ç§»æ°‘äººå£å¤šï¼Œéœ€åŒ»ç”Ÿå…·å¤‡æœåŠ¡å¼±åŠ¿ç¾¤ä½“çš„æ„æ„¿å’Œèƒ½åŠ›ã€‚  

---

### **æ€»ç»“ï¼šå„å›½ä¾§é‡ç‚¹çš„å…±æ€§**  
1. **æ ‡å‡†åŒ–è€ƒè¯•**ï¼šå‡ ä¹æ‰€æœ‰å›½å®¶å‡é€šè¿‡å›½å®¶çº§è€ƒè¯•ç­›é€‰åŸºç¡€èƒ½åŠ›ï¼ˆå¦‚USMLEã€PLABã€AMCï¼‰ã€‚  
2. **æœ¬åœŸåŒ–é€‚åº”**ï¼šåŒ…æ‹¬è¯­è¨€ã€åŒ»ç–—ä½“ç³»ç†Ÿæ‚‰åº¦ã€æ–‡åŒ–æ•æ„Ÿåº¦ï¼ˆå¦‚è‹±å›½NHSã€æ—¥æœ¬ç ”ä¿®åˆ¶åº¦ï¼‰ã€‚  
3. **é•¿æœŸèŒä¸šæ½œåŠ›**ï¼šç¾å›½é‡è§†åŸ¹è®­å®Œæˆåº¦ï¼Œæ¾³æ´²ä¸åŠ æ‹¿å¤§å…³æ³¨å³æˆ˜åŠ›ï¼Œå¾·å›½ä¸æ—¥æœ¬åˆ™å¼ºè°ƒä¸“ä¸šæ·±åº¦ä¸ç¨³å®šæ€§ã€‚  



## ğŸ¥ ä½é™¢é†«å¸«åŸ¹è¨“æ·˜æ±°ç‡è¼ƒé«˜çš„å°ˆç§‘

æ ¹æ“šéå»åå¹´çš„æ•¸æ“šï¼Œä»¥ä¸‹æ˜¯æ·˜æ±°ç‡è¼ƒé«˜çš„å°ˆç§‘ï¼šï¼ˆè‡ºç£ã€ç¾åœ‹ã€æ¾³æ´²æƒ…æ³å¤§åŒå°ç•°ï¼Œä»¥ä¸‹æ˜¯ç¾åœ‹æ•¸æ“šï¼‰

* **ç²¾ç¥ç§‘ï¼ˆPsychiatryï¼‰**ï¼šä¸­ä½æ·˜æ±°ç‡ç‚º 7.53%ï¼Œç‚ºæ‰€æœ‰å°ˆç§‘ä¸­æœ€é«˜ã€‚
* **å¤–ç§‘ï¼ˆSurgeryï¼‰**ï¼šä¸­ä½æ·˜æ±°ç‡ç‚º 3.37%ã€‚
* **ç—…ç†å­¸ï¼ˆPathology - Anatomic and Clinicalï¼‰**ï¼šä¸­ä½æ·˜æ±°ç‡ç‚º 2.91%ã€‚
* **ç¥ç¶“å¤–ç§‘ï¼ˆNeurological Surgeryï¼‰**ï¼šä¸­ä½æ·˜æ±°ç‡ç‚º 2.43%ã€‚
* **å®¶åº­é†«å­¸ï¼ˆFamily Medicineï¼‰**ï¼šä¸­ä½æ·˜æ±°ç‡ç‚º 2.21%ã€‚
* **å©¦ç”¢ç§‘ï¼ˆObstetrics and Gynecologyï¼‰**ï¼šä¸­ä½æ·˜æ±°ç‡ç‚º 1.94%ã€‚

çš®è†šç§‘ï¼ˆDermatologyï¼‰çš„ä¸­ä½æ·˜æ±°ç‡åƒ…ç‚º 0.46%ï¼Œç‚ºæ·˜æ±°ç‡æœ€ä½çš„å°ˆç§‘ã€‚

ç¾åœ‹ä½é™¢é†«å¸«åŸ¹è¨“æ·˜æ±°ç‡æœ€é«˜çš„é†«é™¢: Jackson Memorial Hospital, Miami, FL



## é€Ÿæˆï¼ˆè¨“ç·´å¹´é™æœ€çŸ­ï¼‰å°ˆç§‘
è‡ºç£ï¼šè·æ¥­é†«å­¸ç§‘ã€å…’ç§‘ã€å…§ç§‘

æ¾³æ´²ï¼šæ€§é†«å­¸ç§‘ã€å®¶åº­é†«å­¸ç§‘

ç¾åœ‹ï¼šå®¶åº­é†«å­¸ç§‘ã€å…§ç§‘ã€å…’ç§‘

å…§ç§‘æ¬¡å°ˆç§‘æ°¾æ¿«ï¼Œå¯èƒ½å°ˆç§‘ä¸å¤ ã€‚



---
ç¾åœ‹ Step 2 CK å’Œæ¨è–¦ä¿¡ä¹‹å¤–çš„å°åŠ åˆ†é …ç›®:
1. åœ¨Matchç³»çµ±ä¸Šä¸€å®šè¦é¸signalã€‚
2. é‡å°é†«é™¢å®¢è£½åŒ–æ›¸å¯©è³‡æ–™ï¼Œå‹¿å°‡åŒä»½æ›¸å¯©è³‡æ–™ä¸Ÿçµ¦å¤šå®¶é†«é™¢ã€‚
3. è¯çµ¡åœ°å€å’Œè¯çµ¡é›»è©±å¯«ç¾åœ‹åœ‹å…§çš„ï¼Œå³ä½¿ä½ ä¸æ‰“ç®—çºŒç§Ÿå¯¦ç¿’ä½è™•ã€‚å¯«åœ‹å¤–çš„å¯èƒ½è¢«èª¤èªç‚ºä¾†äº‚çš„ã€‚ï¼ˆç¾åœ‹éƒ½å¸‚å‚³èªªï¼šåªæœ‰10åç¼ºé¡çš„ç§‘å®¤æœ‰æ™‚æ¹§å…¥ä¸Šåƒåæ²’æœ‰zip codeçš„ç”³è«‹äººï¼Œå¥½ä¼¼å¹½éˆäººå£ï¼Œåªå¥½å…¨é¸åˆªé™¤ã€‚ï¼‰

---



**å»ºè­°é¸æ“‡**ï¼š  
- **æƒ³ç©©å®šåŸ·æ¥­** â†’ å¾·åœ‹ã€æ—¥æœ¬ã€‚  
- **æŒ‘æˆ°é«˜è–ª** â†’ ç¾åœ‹ã€‚  
- **è‹±èªç³»åœ‹å®¶** â†’ ç¾åœ‹ã€è‹±åœ‹ã€æ¾³æ´²ã€‚





---

### **å¦‚ä½•é¸æ“‡é©åˆä½ çš„è€ƒè©¦ï¼Ÿ**  
- **æ“…é•·æ·±åº¦æ€è€ƒ** â†’ é¸ **ç¾åœ‹ã€å¾·åœ‹**ï¼ˆéœ€ç†è§£æ©Ÿåˆ¶ï¼‰ã€‚  
- **æ“…é•·å»£åº¦è¨˜æ†¶** â†’ é¸ **å°ç£ã€ä¸­åœ‹**ï¼ˆé¡Œåº«å°å‘ï¼‰ã€‚  
- **é‡è¦–è‡¨åºŠå¯¦å‹™** â†’ é¸ **æ¾³æ´²ã€è‹±åœ‹**ï¼ˆæƒ…å¢ƒæ‡‰ç”¨ï¼‰ã€‚  

**é™„è¨»**ï¼š  
- ç¾åœ‹ USMLE é›–æ”¹ç‚º P/Fï¼Œä½† **Step 2 CK ä»æ˜¯æ·±åº¦+å»£åº¦ç¶œåˆæŒ‘æˆ°**ã€‚  
- å°ç£è¿‘å¹´ç¬¬äºŒéšæ®µæ·±åº¦é€æ¼¸æå‡ã€‚  



---

### ğŸ§ ã€è€ƒè©¦ vs è‡¨åºŠæ€ç¶­é€ŸæŸ¥è¡¨ã€‘å…§ç§‘ç¯‡

| é¡Œå‹/ç‹€æ³              | è€ƒè©¦é‚è¼¯ï¼ˆé¸é€™å€‹æ‰å°ï¼‰                                                                | è‡¨åºŠç¾å¯¦ï¼ˆé‚„è¦è€ƒæ…®é€™äº›ï¼‰                             |
| ------------------ | -------------------------------------------------------------------------- | ---------------------------------------- |
| **è‚ºç‚ï¼ˆå¸å…¥ vs CAPï¼‰**  | æ ¹æ“š **X-rayéƒ¨ä½** + **ç—°æŸ“è‰²èŒç¨®**<br>å¦‚ï¼šå³ä¸Šè‚º + G(+) diplococci â†’ CAPï¼ˆS. pneumoniaeï¼‰ | æœ‰ç„¡ **ä¸­é¢¨ã€ååš¥éšœç¤™ã€æ„è­˜ä¸æ¸…** ç­‰å¸å…¥é¢¨éšªä¹Ÿå¾ˆé‡è¦ï¼Œå¯¦å‹™å¸¸åŒæ™‚è¦†è“‹å­æ°§èŒ |
| **æ•—è¡€æ€§ä¼‘å…‹ vs éæ•æ€§ä¼‘å…‹** | è‹¥ã€Œç™¼ç‡’ + æ„ŸæŸ“è·¡è±¡ã€â†’ æ•—è¡€ç—‡<br>è‹¥ã€Œè—¥ç‰©å¾Œ10åˆ†é˜ã€çš®ç–¹ã€å–˜ã€â†’ éæ•æ€§ä¼‘å…‹ï¼ˆepinephrine firstï¼‰             | ç¾å¯¦ä¸­å…©è€…å¯èƒ½äº¤ç–Šï¼Œæ²»ç™‚å¸¸éœ€ä¸¦è¡Œï¼šæµé€Ÿå¿«ã€epinephrineã€æŠ—ç”Ÿç´ ç­‰    |
| **æŠ—ç”Ÿç´ é¸æ“‡**          | æ ¹æ“šã€Œåˆæ­¥æŸ“è‰²çµæœ + è‚ºç‚ç¤¾å€ vs é†«é™¢ã€                                                    | è‡¨åºŠä¸ŠæœƒåŠ ä¸Šï¼š**æœ€è¿‘ä½é™¢å²ã€ä½¿ç”¨æŠ—ç”Ÿç´ å²ã€æ”¯æ°£ç®¡æ“´å¼µç—‡ç­‰çµæ§‹æ€§è‚ºç—…**     |
| **ä½é™¢èˆ‡å¦**           | ä¾ç…§ **CURB-65 / PSI** é¡Œç›®æè¿°åˆ¤æ–·ï¼ˆå¦‚å¹´é½¡ > 65ã€æœ‰æ„è­˜è®ŠåŒ–ã€å‘¼å¸å¿«ï¼‰                            | è‡¨åºŠé‚„æœƒçœ‹ç¤¾ç¶“ç‹€æ³ã€æœè—¥èƒ½åŠ›ã€å®¶å±¬é…åˆåº¦ç­‰                    |
| **DKA vs HHS**     | é«˜è¡€ç³– + é…®é…¸ä¸­æ¯’ â†’ DKA<br>é«˜è¡€ç³– + æ„è­˜è®Šå·®ã€è¡€æ¼¿æ»²é€å£“é«˜ â†’ HHSï¼ˆè€å¹´äººï¼‰                           | ç¾å¯¦ä¸­ï¼Œè¨±å¤šè€ç—…äººå…©è€…æœƒæ··åˆï¼Œæ²»ç™‚éœ€å…¼é¡§                     |
| **æ€¥æ€§è…æå‚·è™•ç½®**        | é«˜è¡€é‰€ + å°‘å°¿ + æ„è­˜æ”¹è®Š â†’ è¡€æ¶²é€æï¼ˆdialysisï¼‰                                           | æœ‰æ™‚é‚„å¯è€ƒæ…®åˆ©å°¿åŠ‘æŒ‘æˆ°ï¼Œæˆ–ç”¨éˆ£é›¢å­ç©©å®šå¿ƒè‚Œå¾Œå†å®‰æ’é€æ              |
| **å¿ƒé›»åœ–åˆ¤è®€** | çœ‹åˆ°atrial flutter å…¸å‹å¿ƒé›»åœ–ï¼Œåˆ¤æ–·ç‚ºatrial flutter| å…ˆæ‰“adenosine çœ‹çœ‹æ˜¯ä¸æ˜¯PSVT |
| **ä½è¡€é‰€è©•ä¼°** | ä½¿ç”¨ä½è¡€é‰€è©•ä¼°æµç¨‹åœ–æ‰¾åŸå›  | ç”¨é€²é£Ÿç‹€æ³å’Œè—¥ç‰©å²æ‰¾åŸå› ï¼Œç„¶å¾Œè£œé‰€å’Œèª¿æ•´è—¥ç‰©ï¼Œè‹¥è¡€é‰€æ¢å¾©æ­£å¸¸å‰‡ä¸éœ€å†è©•ä¼° |

---

### ğŸ§ ã€è€ƒè©¦ vs è‡¨åºŠæ€ç¶­é€ŸæŸ¥è¡¨ã€‘å¤–ç§‘ç¯‡

| é¡Œå‹/ç‹€æ³                    | è€ƒè©¦é‚è¼¯ï¼ˆé¸é€™å€‹æ‰å°ï¼‰                                                                            | è‡¨åºŠç¾å¯¦ï¼ˆé‚„è¦è€ƒæ…®é€™äº›ï¼‰                                        |
| ------------------------ | -------------------------------------------------------------------------------------- | --------------------------------------------------- |
| **æ€¥æ€§é—Œå°¾ç‚**                | å¹´è¼•äºº + å³ä¸‹è…¹ç—› + McBurney pointå£“ç—› Â± ç™¼ç‡’ â†’ é–‹åˆ€ï¼ˆlap appyï¼‰                                      | å½±åƒï¼ˆUS/CTï¼‰ä»é‡è¦ï¼Œè€äºº/å…’ç«¥è¡¨ç¾ä¸å…¸å‹ï¼Œæœ‰æ™‚å…ˆè§€å¯Ÿ/æŠ—ç”Ÿç´                    |
| **è†½å›Šç‚ vs è†½çŸ³ç—‡**           | ç™¼ç‡’ + å³ä¸Šè…¹ç—› + Murphy signé™½æ€§ â†’ è†½å›Šç‚ï¼ˆæŠ—ç”Ÿç´  + é–‹åˆ€ï¼‰<br>ç„¡ç™¼ç‡’ã€å–®ç´”å³ä¸Šè…¹ç—› â†’ è†½çŸ³ç—‡ï¼ˆä¸ä¸€å®šè¦é–‹åˆ€ï¼‰                  | å¯¦å‹™ä¸Šï¼Œç—…äººå¸¸ä¾†å›åè¦†ç—›å¤šæ¬¡æ‰å®‰æ’æ‰‹è¡“ï¼Œæœ‰æ™‚å…ˆåš ERCP                       |
| **è…¸é˜»å¡ï¼ˆSBOï¼‰**             | åè¦†å˜”å + ç„¡æ’æ°£ + è…¹éƒ¨ Xå…‰ â†’ SBOï¼ˆå…ˆç¦é£Ÿã€é¼»èƒƒç®¡ã€è£œæ°´ï¼‰                                                   | è‹¥æ‡·ç–‘**çµçª„/å£æ­»ï¼ˆfever, leukocytosis, peritonitisï¼‰â†’ æ€¥é–‹åˆ€** |
| **ç©¿å­”æ€§æ½°ç˜**                | çªç™¼åŠ‡ç—› + æ¿ç‹€è…¹ + Xå…‰ free air â†’ æ€¥è¨ºé–‹åˆ€                                                        | æœ‰äº›ç©©å®šç—…äººã€ç©¿å­”å°å¯å…ˆä¿å®ˆæ²»ç™‚ï¼ˆPPI + æŠ—ç”Ÿç´ ï¼‰                         |
| **è…¹ä¸»å‹•è„ˆç˜¤ç ´è£‚ï¼ˆAAA ruptureï¼‰** | è€äºº + çªç™¼èƒŒç—›/è…¹ç—› + ä½è¡€å£“ â†’ ç·Šæ€¥é–‹åˆ€ï¼ˆæˆ–EVARï¼‰                                                       | CT ä»å¸¸ç”¨ä¾†ç¢ºèªè¨ºæ–·ï¼Œä½† unstable æ™‚ç«‹å³æ‰‹è¡“å„ªå…ˆ                      |
| **å¤–ç§‘æ„ŸæŸ“ï¼ˆå¦‚å£æ­»æ€§ç­‹è†œç‚ï¼‰**        | ç™¼ç‡’ + åŠ‡ç—› + çš®è†šæ”¹è®Š â†’ å»£æ•ˆæŠ—ç”Ÿç´  + ç«‹å³æ¸…å‰µæ‰‹è¡“                                                        | ç¾å¯¦ä¸­å¸¸ delayï¼Œä¸€é–‹å§‹èª¤ç•¶èœ‚çª©æ€§çµ„ç¹”ç‚ï¼ˆcellulitisï¼‰ï¼Œè¦å­¸æœƒé«˜åº¦æ‡·ç–‘          |
| **è¡“å¾Œç™¼ç‡’**                 | ä¾ç…§æ™‚é–“åˆ†ï¼š**Wind (è‚º), Water (UTI), Wound (å‚·å£), Walk (DVT), Wonder drug**<br>å¦‚ç¬¬3å¤©ç™¼ç‡’ â†’ è‚ºç‚æœ€å¸¸è¦‹ | ç¾å¯¦ä¸­å¸¸åˆä½µæ„ŸæŸ“ + å…¶ä»–åŸå› ï¼Œè¨ºæ–·è¦é è¡€æ¶²ã€å°¿æ¶²ã€å½±åƒç­‰åˆ¤æ–·                     |
| **å¤–ç§‘é‡ç—‡ç—…äººè¼¸æ¶²ç­–ç•¥**           | è¡€å£“ä½ã€ç„¡å°¿ â†’ é¦–é¸å¤§é‡ IV fluid resuscitationï¼ˆé€šå¸¸ NSï¼‰                                            | é•·æœŸè¼¸æ¶²éœ€è©•ä¼°æ¶²é«”éè² è·ã€electrolyteï¼Œå¸¸éœ€æ› LRã€albumin             |

| é¡Œå‹/ç‹€æ³                  | è€ƒè©¦é‚è¼¯ï¼ˆé¸é€™å€‹æ‰å°ï¼‰                                                                       | è‡¨åºŠç¾å¯¦ï¼ˆå¯¦éš›è€ƒé‡æœƒæ›´å¤šï¼‰                                          |
| ---------------------- | --------------------------------------------------------------------------------- | ------------------------------------------------------ |
| **æ€¥æ€§è…¹ç—›ï¼ˆéœ€æ‰‹è¡“ vs ä¿å®ˆï¼‰**    | è€ƒè©¦å¼·èª¿**å…¸å‹ç—…ç¨‹ + èº«é«”æª¢æŸ¥**ï¼ˆå¦‚ï¼šåå½ˆç—›ã€å›ºå®šå£“ç—›ï¼‰<br>â†’ æ€¥æ€§é—Œå°¾ç‚ã€è…¸é˜»å¡ã€è†½å›Šç‚ç­‰ â†’ æ‰‹è¡“æˆ–è‡³å°‘ä½é™¢è§€å¯Ÿ                   | å¯¦å‹™ä¸Šä¹Ÿçœ‹**å½±åƒã€æŠ½è¡€ã€ç–¼ç—›æ§åˆ¶æ•ˆæœ**ï¼Œä¸”ä¸ä¸€å®šæ¯å€‹å…¸å‹ç—…äººéƒ½ç«‹åˆ»é€²åˆ€æˆ¿                 |
| **è…¸é˜»å¡ï¼ˆobstructionï¼‰è™•ç½®** | **å®Œå…¨é˜»å¡/ç¹¼ç™¼æ€§è…¹è†œç‚** â†’ æ‰‹è¡“<br>**ä¸å®Œå…¨é˜»å¡/ç„¡ peritonitis** â†’ åˆæœŸä¿å®ˆï¼ˆç¦é£Ÿã€NG tubeï¼‰                | æœ‰äº›é«˜é½¡ç—…äººæˆ–å¾©ç™¼æ€§é˜»å¡ç—…äººï¼Œå¸¸è¦é‡è¤‡è©•ä¼°æˆ–å¤šæ¬¡ä¿å®ˆæ²»ç™‚ï¼Œéä¸€åˆ€äº†äº‹                     |
| **è¡“å¾Œæ€¥æ€§ç—‡ç‹€ï¼ˆç–¼ç—›ã€ä½è¡€å£“ã€è…¸éº»ç—ºï¼‰** | è‹¥æ˜¯**å¿ƒè·³â†‘ã€è¡€å£“â†“**ã€è¡“é‡å‡ºè¡€é¢¨éšªé«˜ â†’ å„ªå…ˆè€ƒæ…® **è¡“å¾Œå‡ºè¡€ / anastomosis leak**ï¼Œéœ€å›åˆ€                      | æœ‰æ™‚åŸå› å¯èƒ½æ˜¯ç–¼ç—›æ§åˆ¶ä¸ä½³ã€hypovolemiaã€æˆ–å°¿æ½´ç•™ï¼Œéæ¯æ¬¡éƒ½éœ€ re-open           |
| **ä¹³ç™Œæ‰‹è¡“é¸æ“‡**             | è€ƒè©¦çœ‹ **å¹´é½¡ + è…«ç˜¤å¤§å° + æœ‰ç„¡è½‰ç§»**<br>â†’ < 5cm å¯åšä¹³æˆ¿ä¿ç•™è¡“ï¼ˆBCSï¼‰ï¼Œè‹¥ HER2+ åŠ æ¨™é¶æ²»ç™‚                    | å¯¦å‹™æœƒè€ƒæ…®ç—…äººæ„é¡˜ã€ä¿éšªçµ¦ä»˜ã€ç—…äººèƒ½å¦è¿½è¹¤æ”¾ç™‚ç­‰                               |
| **è†½å›Šç‚è™•ç½®æ™‚æ©Ÿ**            | æ€¥æ€§è†½å›Šç‚ â†’ è‹¥**æ‰‹è¡“é¢¨éšªå¯æ¥å—** â†’ è€ƒè©¦æœƒé¸ **72å°æ™‚å…§é–‹åˆ€**                                           | è‹¥åˆä½µè†½ç®¡ç‚ã€æ•—è¡€ç—‡ã€æˆ– ASA class â†‘ï¼Œè‡¨åºŠå¸¸å…ˆ ERCP + æŠ—ç”Ÿç´  + å»¶å¾Œæ‰‹è¡“        |
| **è¡“å‰ç¦é£Ÿæ™‚é–“**             | è€ƒè©¦å¼·èª¿ï¼š<br>- å›ºé«”é£Ÿç‰©ï¼š**6å°æ™‚**å‰ç¦<br>- æ¸…æ°´ï¼š**2å°æ™‚**å‰ç¦                                       | å¯¦å‹™æœƒä¾ç—…äººç‹€æ³å¾®èª¿ï¼Œä½†è€ƒè©¦å‹™å¿…èƒŒèª¦ **ASA fasting guidelines**          |
| **å¤–å‚·æ€§å‡ºè¡€ï¼ˆæ­¢è¡€ç­–ç•¥ï¼‰**        | è‹¥ç”Ÿå‘½å¾µè±¡ä¸ç©© + è…¹éƒ¨æ“´å¤§ â†’ é–‹è…¹æ­¢è¡€ï¼ˆDamage Control Surgeryï¼‰<br>å››è‚¢å¤§å‡ºè¡€ â†’ Tourniquet or å£“è¿«         | æœ‰æ™‚ä¹Ÿæœƒé¸æ“‡ä»‹å…¥æ€§æ “å¡ï¼ˆIR embolizationï¼‰ï¼Œä½†è€ƒè©¦ä¸æœƒæ”¾å¤ªç´°çš„é¸é …ï¼ˆé™¤éå• IR vs æ‰‹è¡“ï¼‰ |
| **é–‹åˆ€åŒæ„æ›¸çš„å‘ŠçŸ¥å…§å®¹**         | è€ƒè©¦å¼·èª¿ï¼šã€Œéœ€å‘ŠçŸ¥**æ›¿ä»£æ–¹æ¡ˆã€é¢¨éšªã€é å¾Œã€ä¸å¯é æœŸä½µç™¼ç—‡**ã€                                                  | ç¾å¯¦ä¸­é‚„è¦è€ƒæ…®èªè¨€èƒ½åŠ›ã€ç—…äººç†è§£ç¨‹åº¦ã€å®¶å±¬æ„è¦‹ç­‰                               |
| **æ°£èƒ¸å¼•æµï¼ˆèƒ¸ç®¡æ”¾ç½®ï¼‰é©æ‡‰ç—‡**      | è€ƒè©¦æ˜å¯« tension pneumothorax â†’ **ç«‹å³æ”¾é‡æ¸›å£“**<br>Large pneumothorax + å‘¼å¸å–˜ â†’ æ”¾ chest tube | è‡¨åºŠä¹Ÿæœƒè§€å¯Ÿæ˜¯å¦åè¦†ç™¼ä½œã€æ˜¯å¦æœ‰ underlying COPDï¼Œæ±ºå®šæ˜¯å¦è€ƒæ…®æ‰‹è¡“é é˜²            |

---

### ğŸ§ ã€è€ƒè©¦ vs è‡¨åºŠæ€ç¶­é€ŸæŸ¥è¡¨ã€‘å…’ç§‘ç¯‡

| é¡Œå‹/ç‹€æ³                                  | è€ƒè©¦é‚è¼¯ï¼ˆé¸é€™å€‹æ‰å°ï¼‰                                         | è‡¨åºŠç¾å¯¦ï¼ˆé‚„è¦è€ƒæ…®é€™äº›ï¼‰                                                   |
| -------------------------------------- | --------------------------------------------------- | -------------------------------------------------------------- |
| **æ–°ç”Ÿå…’ç™¼ç‡’**                              | 24å°æ™‚å…§ç™¼ç‡’ + **ç„¡æ˜é¡¯æ„ŸæŸ“ç„¦é»** â†’ è¦–ç‚ºæ•—è¡€ç—‡è™•ç†ï¼ˆæŠ—ç”Ÿç´  + è¡€åŸ¹ï¼‰           | æ–°ç”Ÿå…’ç™¼ç‡’å¸¸éœ€æ’é™¤**å°¿è·¯æ„ŸæŸ“**ï¼Œéœ€è¦åšå°¿æ¶²æª¢æŸ¥å’Œè…¦è†œç‚ç¯©æª¢                                |
| **å¬°å¹¼å…’æ€¥æ€§è…¹ç€‰**                            | æŒçºŒè…¹ç€‰ + è¼•åº¦è„«æ°´ â†’ ç°¡å–®è£œæ°´ã€é›»è§£è³ª                              | åš´é‡è…¹ç€‰ + è„«æ°´ï¼ˆä¾¿è¡€ã€ç™½è¡€çƒå¢é«˜ï¼‰â†’ æ‡·ç–‘è…¸é“æ„ŸæŸ“ï¼ˆä¾‹å¦‚ **Clostridium difficile**ï¼‰éœ€è¦æŠ—ç”Ÿç´  |
| **ä¸Šå‘¼å¸é“æ„ŸæŸ“ï¼ˆURIï¼‰**                        | å…¸å‹æ„Ÿå†’ç—‡ç‹€ï¼šé¼»å¡ã€å–‰åš¨ç—›ã€å’³å—½ â†’ ä¸€èˆ¬æ”¯æŒæ€§æ²»ç™‚                          | è‹¥ç™¼ç‡’ã€å˜”åã€æŒçºŒå’³å—½ â†’ éœ€æ’é™¤ **ç™¾æ—¥å’³**ã€**è‚ºç‚**ï¼Œç‰¹åˆ¥æ˜¯å¹´å¹¼å…’ç«¥                       |
| **æ€¥æ€§æ”¯æ°£ç®¡ç‚ vs å“®å–˜**                       | ç„¡å–˜æ¯éŸ³ã€å¹´ç´€è¼ƒå¤§ â†’ æ”¯æ°£ç®¡ç‚                                    | è‹¥å–˜æ¯éŸ³ + å‘¼å¸å›°é›£ â†’ å“®å–˜ï¼›å°å…’å“®å–˜å¤šè¦‹æ–¼å¹´ç´€è¼ƒå¤§                                   |
| **æ€¥æ€§ä¸­è€³ç‚**                              | çªç™¼è€³ç—› + ç™¼ç‡’ + é¼»å¡ â†’ æ€¥æ€§ä¸­è€³ç‚                              | è‹¥åè¦†æ„ŸæŸ“æˆ–è€³ç—›æŒçºŒï¼Œå¯èƒ½æ˜¯ **æ…¢æ€§ä¸­è€³ç‚**ï¼Œéœ€è¦æ’é™¤è€³é“ç•°ç‰©æˆ–è€³è†œç©¿å­”                         |
| **å…’ç«¥ç™¼ç‡’**                               | ç„¡æ˜ç¢ºç„¦é» + æŒçºŒç™¼ç‡’ â†’ éœ€è¦æ’é™¤ **å°¿è·¯æ„ŸæŸ“ã€è…¦è†œç‚ã€æ•—è¡€ç—‡**                | å¯¦å‹™ä¸­ï¼Œç™¼ç‡’å¸¸å› ç—…æ¯’æ„ŸæŸ“ï¼ˆå¦‚**RSVã€æµæ„Ÿ**ï¼‰ï¼Œéœ€è€ƒæ…®å¹´é½¡åŠæš´éœ²å²                            |
| **è…¸å¥—ç–Š**                                | **æ€¥æ€§è…¹ç—› + å˜”å + ä¹¾å˜”** â†’ é«˜ç–‘æ…®è…¸å¥—ç–Šï¼Œé ˆç«‹åˆ»é€²è¡Œè¶…éŸ³æ³¢æª¢æŸ¥              | è…¸å¥—ç–Šå¯è¦‹æ–¼å©´å¹¼å…’ï¼Œç‰¹åˆ¥æ˜¯6å€‹æœˆä»¥ä¸‹ï¼Œæ€¥è¨ºå½±åƒè¨ºæ–·å¾Œå¯è€ƒæ…®æ°£å›Šæ²»ç™‚æˆ–æ‰‹è¡“                           |
| **å°å…’éæ•æ€§ç´«æ–‘ç—‡ï¼ˆHenoch-Schonlein Purpuraï¼‰** | **ç´«æ–‘ + è…¹ç—› + è…åŠŸèƒ½å—æ** â†’ Henoch-Schonlein Purpuraï¼ˆHSPï¼‰ | å¯¦å‹™ä¸Šï¼Œè‹¥åˆä½µè…ç—…æˆ–GIå‡ºè¡€ï¼Œéœ€å¯†åˆ‡è¿½è¹¤è…åŠŸèƒ½ã€æ§åˆ¶ç—‡ç‹€                                   |
| **æ–°ç”Ÿå…’é»ƒç–¸**                              | ç”Ÿç†æ€§é»ƒç–¸ï¼šé€šå¸¸3-5å¤©é–‹å§‹ï¼Œæœ€å¤š7-10å¤©æ¶ˆé€€ï¼›è‹¥è¶…é14å¤©ï¼Œéœ€é€²ä¸€æ­¥æª¢æŸ¥              | è‹¥è†½ç´…ç´ éé«˜ï¼ˆ>20 mg/dLï¼‰æˆ–æ€¥æ€§é»ƒç–¸ç™¼ä½œâ†’ æ‡·ç–‘ **è‚ç—…** æˆ–**æ„ŸæŸ“**ï¼Œè¦åšæ›´å¤šæª¢æŸ¥             |
| **ç•°ä½æ€§çš®è†šç‚ï¼ˆæ¿•ç–¹ï¼‰**                         | ä¹¾ç‡¥ã€ç˜™ç™¢ã€ç´…æ–‘ã€é±—å±‘ â†’ ä½¿ç”¨ä¿æ¿•åŠ‘ã€å±€éƒ¨é¡å›ºé†‡                           | å¯¦å‹™ä¸Šï¼Œå¯èƒ½èˆ‡é£Ÿç‰©éæ•ã€ç’°å¢ƒå› ç´ ç›¸é—œï¼Œæ‡‰æ³¨æ„éæ•æºèˆ‡ç®¡ç†                                   |

---

### ğŸ§ ã€è€ƒè©¦ vs è‡¨åºŠæ€ç¶­é€ŸæŸ¥è¡¨ã€‘å©¦ç”¢ç§‘ç¯‡

| é¡Œå‹/ç‹€æ³                | è€ƒè©¦é‚è¼¯ï¼ˆé¸é€™å€‹æ‰å°ï¼‰                                                                                     | è‡¨åºŠç¾å¯¦ï¼ˆå¯¦éš›è€ƒé‡æœƒæ›´å¤šï¼‰                               |
| -------------------- | ----------------------------------------------------------------------------------------------- | ------------------------------------------- |
| **ç•°å¸¸å­å®®å‡ºè¡€ï¼ˆAUBï¼‰è™•ç½®**    | è‹¥æ’é™¤æœ‰å…¶ä»–å±éšªå› ç´ ï¼ˆå¦‚å­å®®å…§è†œç•°ä½ã€å­å®®è‚Œç˜¤ï¼‰ï¼Œè€ƒè©¦å¸¸é¸ **å£æœé¿å­•è—¥æˆ–é»ƒé«”é…®**<br>è‹¥é‡ç—‡ â†’ **æ­¢è¡€åŠ‘æˆ–å­å®®åˆ®é™¤**                               | è‡¨åºŠä¸Šé‚„æœƒè€ƒæ…®æ‚£è€…å¹´é½¡ã€ç—…å²ï¼ˆå¦‚å¤šæ¬¡æµç”¢ã€æ¿€ç´ ç™‚æ³•éæ•ç­‰ï¼‰ï¼Œä¹Ÿè¨±æœƒé¸æ“‡å±€éƒ¨æˆ–å…¨èº«æ²»ç™‚  |
| **å¦Šå¨ æœŸé«˜è¡€å£“ vs å­ç™‡å‰ç—‡**   | **å­ç™‡å‰ç—‡**é€šå¸¸æœ‰**è›‹ç™½å°¿ã€è¦–åŠ›æ”¹è®Šã€å³ä¸Šè…¹ç—›**ç­‰ï¼Œå¿…é ˆé¸ **é™å£“è—¥** ä¸¦å¯†åˆ‡ç›£æ§                                                 | ç¾å¯¦ä¸­ï¼Œæœƒæ ¹æ“šç—…äººç—‡ç‹€å’Œå±éšªå› ç´ ï¼ˆå¦‚æ—©æœŸé«˜è¡€å£“æˆ–å®¶æ—å²ï¼‰ä¾†èª¿æ•´æ²»ç™‚æ–¹æ¡ˆ         |
| **å®®å¤–å­•è¨ºæ–·**            | è€ƒè©¦å¼·èª¿ **B-hCG ä½è€Œä¸Šå‡ç·©æ…¢** + **é™°é“è¶…éŸ³æ³¢é¡¯ç¤ºç©ºçš„å­å®®**ï¼Œé¸æ“‡ **è—¥ç‰©æ²»ç™‚**ï¼ˆMethotrexateï¼‰æˆ–æ‰‹è¡“                            | å¯¦å‹™ä¸­ï¼Œæœƒæ ¹æ“šæ˜¯å¦æœ‰ç”Ÿå‘½å¾µè±¡ä¸ç©©ã€å…§å‡ºè¡€é‡ï¼Œé¸æ“‡æ˜¯å¦é–‹åˆ€æˆ–ä½¿ç”¨è—¥ç‰©           |
| **å¦Šå¨ ç³–å°¿ç—…è¨ºæ–·**          | ä½¿ç”¨ **OGTTï¼ˆå£æœè‘¡è„ç³–è€å—æ¸¬è©¦ï¼‰**ï¼Œè‹¥ **FBS > 92mg/dL** æˆ– **1å°æ™‚ > 180mg/dL**ï¼Œå¯è¨ºæ–·å¦Šå¨ ç³–å°¿ç—…                        | å¯¦å‹™ä¸Šï¼Œæœƒæ›´é—œæ³¨ç—…äººçš„BMIã€å®¶æ—ç—…å²ã€é£²é£Ÿç¿’æ…£ç­‰é•·æœŸç®¡ç†               |
| **ç”¢å¾Œå‡ºè¡€è™•ç½®**           | è‹¥ç„¡æ³•æ§åˆ¶å‡ºè¡€ï¼Œé¸æ“‡ **å­å®®æŒ‰æ‘© + Oxytocin**ï¼Œè‹¥æŒçºŒå‡ºè¡€ï¼Œé¸æ“‡**å­å®®å‹•è„ˆæ “å¡æˆ–å­å®®åˆ‡é™¤**                                          | åœ¨è‡¨åºŠä¸­ï¼Œå¸¸æœƒæª¢æŸ¥å‡ºè¡€æºï¼Œè€ƒæ…®æ˜¯å¦ç‚ºå­å®®æ’•è£‚æˆ–èƒç›¤æ®˜ç•™ç­‰æƒ…æ³ï¼Œä¸¦é€²è¡Œä¿®è£œæˆ–æ¸…é™¤     |
| **å¦Šå¨ é«˜è¡€å£“ vs å­ç™‡ç—‡ç‹€çš„é‘‘åˆ¥** | è‹¥å‡ºç¾ **è¦–åŠ›æ¨¡ç³Šã€é ­ç—›ã€ä¸Šè…¹ç—›ï¼Œä¸”æœ‰é«˜è¡€å£“**ï¼Œæ‡‰é¸æ“‡ **é™å£“è—¥ç‰©** æˆ–é€²è¡Œ **ä½é™¢ç›£è­·**                                             | å¯¦å‹™ä¸Šï¼ŒæœƒåŠ å¼·**å°¿è›‹ç™½æ¸¬è©¦ã€è¡€æ¶²æª¢æŸ¥ã€è‚åŠŸèƒ½æ¸¬è©¦**ç­‰ç¶œåˆè¨ºæ–·ï¼Œä¸¦é©æ™‚ä½¿ç”¨æŠ—ç™²ç™‡è—¥ç‰© |
| **å©¦ç§‘ç™Œç—‡ç¯©æª¢**           | \*\*ä¹³ç™Œç¯©æª¢ï¼š\*\*å¹´æ»¿50æ­²ï¼Œæ¯å…©å¹´ä¹³æˆ¿æ”å½±<br>**å®®é ¸ç™Œç¯©æª¢ï¼š** 21-65æ­²ï¼Œæ¯3å¹´é€²è¡Œ Pap smear<br>\*\*åµå·¢ç™Œç¯©æª¢ï¼š\*\*åƒ…åœ¨é«˜é¢¨éšªç—…äººä¸­ï¼ˆå®¶æ—å²ç­‰ï¼‰ | åœ¨è‡¨åºŠä¸­ï¼ŒæœƒåŸºæ–¼å®¶æ—å²ã€éå»ç—…å²ï¼ˆå¦‚å¤šæ¬¡æµç”¢æˆ–æ¿€ç´ æ²»ç™‚ç­‰ï¼‰é€²è¡Œç¯©æª¢           |
| **å‰–è…¹ç”¢çš„é©æ‡‰ç—‡**          | **æ‡·ç–‘èƒä½ä¸æ­£æˆ–èƒå…’éå¤§ï¼Œç¶“é™°é“åˆ†å¨©ç„¡æ³•é †åˆ©é€²è¡Œ** â†’ å¿…é ˆé¸æ“‡å‰–è…¹ç”¢                                                           | å¯¦éš›æ“ä½œä¸­ï¼Œé™¤äº†èƒä½ã€èƒå…’å¤§å°ï¼Œé‚„æœƒæ ¹æ“šæ¯é«”ç—…å²ï¼ˆå¦‚éª¨ç›†ç‹¹çª„ã€ä¹‹å‰å‰–è…¹ç”¢ç­‰ï¼‰ä¾†è€ƒæ…®   |
| **å­å®®è‚Œç˜¤è™•ç½®**           | è‹¥ç‚ºç—‡ç‹€æ€§è‚Œç˜¤ï¼Œä¸¦ä¸”æœªè¨ˆåŠƒæ‡·å­•ï¼Œé¸æ“‡ **è—¥ç‰©æ²»ç™‚**ï¼ˆGnRHæ¿€å‹•åŠ‘ï¼‰æˆ–**å­å®®åˆ‡é™¤è¡“**                                                  | è‡¨åºŠä¸Šï¼Œæœƒè€ƒæ…®æ‚£è€…çš„å¹´é½¡ã€æ˜¯å¦è¨ˆåŠƒæ‡·å­•ã€è‚Œç˜¤çš„ä½ç½®å’Œå¤§å°ç­‰ï¼Œé¸æ“‡ä¿å®ˆæˆ–ä¾µå…¥æ€§æ²»ç™‚    |




## å…¶ä»–ç›¸é—œä½œå“
[OSCEè¤‡ç¿’](https://brucechen034020.github.io/2025TWMLE/OSCE) (2025/4/24)

æ–‡æ¡ˆ:
```
æœ‰äº›åŒå­¸ï¼ˆåŒ…æ‹¬æˆ‘ï¼‰æ˜å¤©è¦è€ƒ OSCEï¼Œæˆ‘æ•´ç†äº†ä¸€ä»½ OSCE å¸¸è¦‹ä¸»è¨´èˆ‡é‘‘åˆ¥è¨ºæ–·å°ç…§æ¸…å–®ï¼Œæ¯å€‹ä¸»è¨´éƒ½åˆ—å‡ºä¸‰å€‹é‘‘åˆ¥è¨ºæ–·ã€‚æˆ‘çš„è¨ˆç•«æ˜¯ï¼šåœ¨è¨ºé–“å¤–è®€é¡Œçš„ 2 åˆ†é˜å…§ï¼Œå…ˆæ ¹æ“šä¸»è¨´å¯«ä¸‹é‘‘åˆ¥è¨ºæ–·ï¼Œé€™æ¨£å•è¨ºæ™‚å¯ä»¥æœ‰æ–¹å‘ï¼Œç¢ºä¿å•åˆ°ç›¸é—œå•é¡Œï¼Œé¿å…éºæ¼ï¼Œèƒ½å¤ èªªå‡º3å€‹é‘‘åˆ¥è¨ºæ–·å’Œæœ€å¯èƒ½çš„è¨ºæ–·ï¼Œå¿ƒæƒ…ä¹Ÿæ¯”è¼ƒä¸æœƒç·Šå¼µã€‚
æä¾›é€™ä»½æ¸…å–®çµ¦å¤§å®¶åƒè€ƒçœ‹çœ‹ï¼š
https://brucechen034020.github.io/2025TWMLE/OSCE
```

[é‘‘åˆ¥è¨ºæ–·ç·´ç¿’](https://brucechen034020.github.io/MedicalSituationPuzzle/) (2022/9/19)

æ–‡æ¡ˆ:
```
è·Ÿå¤§å®¶åˆ†äº«æˆ‘æœ€è¿‘å¯«çš„éŠæˆ² éŠæˆ²è¦å‰‡:
ç¨‹å¼æœƒéš¨æ©Ÿè¼¸å‡ºä¸€å€‹ç–¾ç—…çš„ç—‡ç‹€
ä½ è¦èªªå‡ºæ˜¯ç”šéº¼ç—…
æœƒå…¬å¸ƒç­”æ¡ˆ
https://brucechen034020.github.io/MedicalSituationPuzzle/
```
